IRIT@CRCT
Equipe « MICHEL LAUDET »

IRIT@CRCT :

laboratoire de cancérologie numérique « Michel Laudet »

Le Centre de Recherches en Cancérologie de Toulouse (CRCT) et l’Institut de Recherche en Informatique de Toulouse (IRIT), opère un rapprochement inédit en créant un laboratoire intégré dans les locaux du CRCT. Fruit d’une longue coopération, les chercheurs du CRCT et de l’IRIT ont souhaité se rapprocher afin de pouvoir travailler en synergie au cœur même de l’Oncopole.

Aujourd’hui il est impossible de penser recherche en santé sans penser numérique tant le volume de données à traiter est devenu important. En apportant aux chercheurs du CRCT et de l’IUCT-O des compétences en intelligence artificielle, en mathématique, en simulation, en modélisation logique des systèmes et en vie artificielle, l’IRIT apporte un véritable coup d’accélérateur à la recherche du CRCT et permettra à terme de proposer rapidement des solutions innovantes pour une meilleure prise en charge aux patients atteints de cancer.

Cette collaboration sciences de la vie, sciences de l’informatique, intégrée dans un centre de recherche contre le cancer est une première en France. Ce laboratoire est un exemple réussi de la convergence des sciences de l’informatique vers les sciences de la santé au bénéfice de la recherche en cancérologie et des patients. La localisation sur un même site permet aux chercheurs du CRCT de mieux appréhender les outils de l’Informatique et de l’IA et aux chercheurs de l’IRIT de mieux comprendre les questions essentielles de la cancérologie. Ce laboratoire voit son activité débuter sur une croissance rapide et met en place de nombreux projets ambitieux dans le cadre de la lutte contre le cancer.

C’est dans ce cadre qu’Ibrahim Didi, co-encadré par le Dr Sarah Bertoli (CHU/CRCT) et David Simoncini (IRIT), s’est vu remettre le 02 décembre 2021 un prix de meilleur stage de recherche de l’Ecole Polytechnique pour son travail autour de l’utilisation de techniques d’IA pour la prédiction du pronostic et l’aide à la décision de traitement de la leucémie aiguë myéloïde. Ce travail a été présenté sous forme de poster au congrès de l’American Society of Hematology (2021) et sous forme de communication orale au congrès de la société française d’hématologie (2022).

Le laboratoire Michel Laudet en chiffre

10 chercheurs de l’IRIT – 12 chercheurs du CRCT et de l’IUCT
2 Thèses et 3 post-doctorant
5 stagiaires en moyenne issus notamment des grandes écoles (Polytechnique, INSA Toulouse et École Centrale Paris, École des Mines)
Une dizaine de projets en cours ou émergents

NOS PROJETS
DE RECHERCHE

Observance

Etienne Chatelut et Joseph Gergaud

lire plus

Titre en cours

Camille Franchet et Sylvain Cussat-Blanc

lire plus

Titre en cours

Pierre Brousset, Sylvain Cussat-Blanc

lire plus

LAM

Sarah Bertoli et David Simoncini

lire plus

Modélisation des cartes d’interaction moléculaire

Jean-Marc Alliot et Gilles Favre

lire plus

PRODUCTIONS SCIENTIFIQUES

PUBLICATIONS 2022

7813506 B2CRS8U4 2022 1 chicago-fullnote-bibliography 50 date desc 50518 https://www.crct-inserm.fr/wp-content/plugins/zotpress/

PUBLICATIONS 2021

7813506 B2CRS8U4 2021 1 chicago-fullnote-bibliography 50 date desc 50518 https://www.crct-inserm.fr/wp-content/plugins/zotpress/

PUBLICATIONS 2020

7813506 B2CRS8U4 2020 1 chicago-fullnote-bibliography 50 date desc 50518 https://www.crct-inserm.fr/wp-content/plugins/zotpress/

PUBLICATIONS 2019

7813506 2019 1 chicago-fullnote-bibliography 50 date desc 50518 https://www.crct-inserm.fr/wp-content/plugins/zotpress/

%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A550%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22CC4VZTEM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Delaunay%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-31%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDelaunay%2C%20Myriam%2C%20Gr%26%23xE9%3Bgoire%20Pr%26%23xE9%3Bvot%2C%20Samia%20Collot%2C%20Laurent%20Guilleminault%2C%20Alain%20Didier%2C%20and%20Julien%20Mazi%26%23xE8%3Bres.%20%26%23x201C%3BManagement%20of%20Pulmonary%20Toxicity%20Associated%20with%20Immune%20Checkpoint%20Inhibitors.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Respiratory%20Review%3A%20An%20Official%20Journal%20of%20the%20European%20Respiratory%20Society%26lt%3B%5C%2Fi%26gt%3B%2028%2C%20no.%20154%20%28December%2031%2C%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F16000617.0012-2019%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F16000617.0012-2019%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Management%20of%20pulmonary%20toxicity%20associated%20with%20immune%20checkpoint%20inhibitors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Delaunay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9goire%22%2C%22lastName%22%3A%22Pr%5Cu00e9vot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samia%22%2C%22lastName%22%3A%22Collot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Guilleminault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Didier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Mazi%5Cu00e8res%22%7D%5D%2C%22abstractNote%22%3A%22Immunotherapy%20has%20become%20a%20standard%20of%20care%20in%20oncology%2C%20following%20the%20recent%20approvals%20of%20cytotoxic%20T-lymphocyte-associated%20protein-4%20and%20programmed%20cell%20death-1%20inhibitors%20in%20lung%20cancer%2C%20melanoma%2C%20renal%20cell%20carcinoma%2C%20Hodgkin%26%23039%3Bs%20lymphoma%2C%20bladder%2C%20head%20and%20neck%20cancers.%20Besides%20their%20efficacy%2C%20these%20agents%20also%20generate%20specific%20immune-related%20adverse%20events.%20Due%20to%20the%20increasing%20prescription%20of%20immune-checkpoint%20inhibitors%2C%20the%20incidence%20of%20immune%20toxicity%20will%20continue%20to%20rise.%20The%20awareness%20of%20immune-related%20adverse%20events%20is%20key%20to%20ensuring%20both%20diagnosis%20and%20management%20of%20the%20possible%20serious%20adverse%20events.%20Although%20severe%20immune-related%20adverse%20events%20remain%20rare%2C%20they%20can%20lead%20to%20discontinued%20treatment%20or%20to%20death%20if%20they%20are%20not%20forecasted%20and%20managed%20properly.%20Even%20if%20lung%20toxicity%20is%20not%20the%20most%20frequent%20adverse%20event%2C%20it%20remains%20critical%20as%20it%20can%20be%20life-threatening.%20Herein%2C%20the%20main%20aspects%20of%20pulmonary%20toxicity%20are%20reviewed%20and%20guidelines%20are%20also%20proposed%20in%20order%20to%20manage%20the%20possible%20side-effects.%22%2C%22date%22%3A%22Dec%2031%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1183%5C%2F16000617.0012-2019%22%2C%22ISSN%22%3A%221600-0617%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22BCSJCKVR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ploussard%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-30%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPloussard%2C%20Guillaume%2C%20Jean-Baptiste%20Beauval%2C%20Marine%20Lesourd%2C%20Christophe%20Almeras%2C%20Jacques%20Assoun%2C%20Richard%20Aziza%2C%20Jean-Romain%20Gautier%2C%20et%20al.%20%26%23x201C%3BImpact%20of%20MRI%20and%20Targeted%20Biopsies%20on%20Eligibility%20and%20Disease%20Reclassification%20in%20MRI-Positive%20Candidates%20for%20Active%20Surveillance%20on%20Systematic%20Biopsies.%26%23x201D%3B%20%26lt%3Bi%26gt%3BUrology%26lt%3B%5C%2Fi%26gt%3B%2C%20December%2030%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.urology.2019.10.039%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.urology.2019.10.039%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20MRI%20and%20targeted%20biopsies%20on%20eligibility%20and%20disease%20reclassification%20in%20MRI-positive%20candidates%20for%20active%20surveillance%20on%20systematic%20biopsies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Ploussard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Beauval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Lesourd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Almeras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Assoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Aziza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Romain%22%2C%22lastName%22%3A%22Gautier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Loison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Portalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambroise%22%2C%22lastName%22%3A%22Salin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Tollon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Souli%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Malavaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Roumigui%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20assess%20the%20impact%20of%20concomitant%20targeted%20biopsies%20%28TB%29%20for%20predicting%20final%20disease%20reclassification%20in%20MRI-positive%20low-risk%20prostate%20cancer%20patients%20eligible%20for%20active%20surveillance%20%28AS%29%20on%20systematic%20biopsies%20%28SB%29.%5CnMATERIALS%20AND%20METHODS%3A%20From%20a%20prospective%20database%2C%20we%20included%20all%20pre-biopsy%20MRI-positive%20men%20fulfilling%20AS%20criteria%20at%20diagnosis%20%28Toronto%20%28n%3D114%29%2C%20UCSF%20%28n%3D82%29%2C%20or%20PRIAS%20%28n%3D60%29%20criteria%29%20on%20SB.%20All%20patients%20underwent%20a%20combination%20of%20SB%20and%20software-based%20fusion%20TB%2C%20and%20an%20immediate%20radical%20prostatectomy.%20The%20primary%20endpoints%20were%20the%20pathological%20upgrading%20and%20upstaging%20rates.%5CnRESULTS%3A%20Biopsy%20grade%20group%20was%20upgraded%20to%20GG%202%20and%20to%20GG%5Cu22653%20on%20TB%20in%2065.9%25-76.7%25%20and%20in%2012.2-16.7%25%2C%20respectively.%20The%20rate%20of%20GG%5Cu22653%20in%20RP%20specimens%20varied%20from%2031.6%25%20to%2043.3%25%20with%20no%20relation%20between%20strictest%20criteria%20and%20lower%20upgrading%20rates.%20The%20proportion%20of%20not%20organ-confined%20disease%20%2835-39%25%29%20was%20comparable%20among%20the%20AS%20cohorts.%20Negative%20TB%20was%20strongly%20associated%20with%20the%20absence%20of%20final%20GG%5Cu22653.%20Tumor%20grade%20on%20TB%20was%20significantly%20correlated%20with%20the%20risk%20of%20final%20GG%5Cu22653%20in%20both%20Toronto%20and%20UCSF%20cohorts%2C%20not%20in%20the%20PRIAS%20cohort.%20In%20the%20PRIAS%20cohort%2C%20the%20only%20independent%20predictive%20factor%20for%20GG%5Cu22653%20disease%20was%20the%20maximal%20tumor%20length%20in%20any%20core%20%28p%3D0.034%29.%5CnCONCLUSIONS%3A%20In%20MRI-positive%20patients%2C%20the%20risk%20of%20disease%20reclassification%20was%20comparable%20whatever%20the%20SB-based%20AS%20criteria%20used.%20TB%20were%20predictive%20of%20final%20upgrading%2C%20with%20a%20varied%20impact%20according%20to%20the%20AS%20criteria.%20SB%20features%20remained%20relevant%20for%20reclassification%20prediction%20even%20in%20case%20of%20positive%20TB.%20The%20risk%20of%20upstaged%20disease%20remains%20important%2C%20approximately%20one%20third%2C%20and%20neither%20targeted%5C%2Fsystematic%20biopsy%20parameters%20nor%20MRI%20findings%20could%20accurately%20predict%20it.%22%2C%22date%22%3A%22Dec%2030%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.urology.2019.10.039%22%2C%22ISSN%22%3A%221527-9995%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22CNG8RZJ5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grondin%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-30%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGrondin%2C%20Anthony%2C%20Elo%26%23xEF%3Bse%20Baudou%2C%20Marl%26%23xE8%3Bne%20Pasquet%2C%20Sonia%20Pelluau%2C%20Karim%20Jamal-Bey%2C%20C%26%23xE9%3Bcile%20Bermot%2C%20Frederic%20Villega%2C%20and%20Emmanuel%20Cheuret.%20%26%23x201C%3BNeonatal%20Herpes%20Simplex%20Virus-1%20Recurrence%20with%20Central%20Nervous%20System%20Disease%20in%20Twins%20after%20Completion%20of%20a%20Six-Month%20Course%20of%20Suppressive%20Therapy%3A%20Case%20Report.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeuropediatrics%26lt%3B%5C%2Fi%26gt%3B%2C%20December%2030%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1055%5C%2Fs-0039-3402011%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1055%5C%2Fs-0039-3402011%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neonatal%20Herpes%20Simplex%20Virus-1%20Recurrence%20with%20Central%20Nervous%20System%20Disease%20in%20Twins%20after%20Completion%20of%20a%20Six-Month%20Course%20of%20Suppressive%20Therapy%3A%20Case%20Report%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Grondin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elo%5Cu00efse%22%2C%22lastName%22%3A%22Baudou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marl%5Cu00e8ne%22%2C%22lastName%22%3A%22Pasquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%22%2C%22lastName%22%3A%22Pelluau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karim%22%2C%22lastName%22%3A%22Jamal-Bey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Bermot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Villega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Cheuret%22%7D%5D%2C%22abstractNote%22%3A%22Seventeen-day-old%20twins%20were%20hospitalized%20for%20neonatal%20herpes%20simplex%20virus%201%20%28HSV-1%29%20with%20central%20nervous%20system%20disease%20and%20internal%20capsule%20and%20thalamic%20lesions%20on%20magnetic%20resonance%20imaging%20%28MRI%29.%20They%20were%20treated%20with%20the%20usual%20intravenous%20%28IV%29%20treatment%20and%20oral%20therapy%20for%206%20months.%20The%20clinical%20course%20was%20good%20in%20both%20children%20with%20negative%20HSV%20polymerase%20chain%20reaction%20on%20completion%20of%20IV%20therapy.%20The%20neurological%20condition%20recurred%20in%20one%20child%20with%20new%20radiological%20lesions%20at%207%20months%20of%20age%2C%202%20weeks%20after%20discontinuation%20of%20oral%20treatment.%20Cerebral%20lesions%20highlighted%20on%20the%20MRI%20scan%20are%20specific%20to%20the%20neonatal%20period%20and%20impact%20long-term%20prognosis.%20The%20likely%20genetic%20predisposition%20in%20this%20case%20is%20interesting%20and%20requires%20further%20investigation.%20In%20addition%2C%20this%20case%20raises%20questions%20about%20the%20duration%20of%20oral%20acyclovir%20suppressive%20therapy.%22%2C%22date%22%3A%22Dec%2030%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1055%5C%2Fs-0039-3402011%22%2C%22ISSN%22%3A%221439-1899%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22M46ETUTI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Siegfried%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-30%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSiegfried%2C%20Aurore%2C%20Julien%20Masliah-Planchon%2C%20Franck-Emmanuel%20Roux%2C%20Delphine%20Larrieu-Ciron%2C%20Gaelle%20Pierron%2C%20Yvan%20Nicaise%2C%20Marion%20Gambart%2C%20et%20al.%20%26%23x201C%3BBrain%20Tumor%20with%20an%20ATXN1-NUTM1%20Fusion%20Gene%20Expands%20the%20Histologic%20Spectrum%20of%20NUTM1-Rearranged%20Neoplasia.%26%23x201D%3B%20%26lt%3Bi%26gt%3BActa%20Neuropathologica%20Communications%26lt%3B%5C%2Fi%26gt%3B%207%2C%20no.%201%20%28December%2030%2C%202019%29%3A%20220.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-019-0870-8%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-019-0870-8%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Brain%20tumor%20with%20an%20ATXN1-NUTM1%20fusion%20gene%20expands%20the%20histologic%20spectrum%20of%20NUTM1-rearranged%20neoplasia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Masliah-Planchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck-Emmanuel%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Larrieu-Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaelle%22%2C%22lastName%22%3A%22Pierron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Gambart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Catalaa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Dubucs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Badreddine%22%2C%22lastName%22%3A%22Mohand-Oumoussa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Tirode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Bourdeaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Dec%2030%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40478-019-0870-8%22%2C%22ISSN%22%3A%222051-5960%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22TIEYW3SQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Manrique%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BManrique%2C%20Alain%2C%20David%20Dudoignon%2C%20St%26%23xE9%3Bphanie%20Brun%2C%20Catherine%20N%26%23x2019%3BGanoa%2C%20Emmanuelle%20Cassol%2C%20Damien%20Legallois%2C%20Yoan%20Lavie-Badie%2C%20Denis%20Agostini%2C%20and%20Olivier%20Lairez.%20%26%23x201C%3BQuantification%20of%20Myocardial%2099mTc-Labeled%20Bisphosphonate%20Uptake%20with%20Cadmium%20Zinc%20Telluride%20Camera%20in%20Patients%20with%20Transthyretin-Related%20Cardiac%20Amyloidosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEJNMMI%20Research%26lt%3B%5C%2Fi%26gt%3B%209%2C%20no.%201%20%28December%2023%2C%202019%29%3A%20117.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13550-019-0584-8%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13550-019-0584-8%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Quantification%20of%20myocardial%2099mTc-labeled%20bisphosphonate%20uptake%20with%20cadmium%20zinc%20telluride%20camera%20in%20patients%20with%20transthyretin-related%20cardiac%20amyloidosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Manrique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Dudoignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Brun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22N%27Ganoa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cassol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Legallois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoan%22%2C%22lastName%22%3A%22Lavie-Badie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Agostini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Lairez%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20We%20aimed%20to%20compare%20different%20methods%20for%20semi-quantitative%20analysis%20of%20cardiac%20retention%20of%20bone%20tracers%20in%20patients%20with%20cardiac%20transthyretin%20amyloidosis%20%28ATTR%29.%5CnMETHODS%3A%20Data%20from%2067%20patients%20with%20ATTR%20who%20underwent%20both%20conventional%20whole-body%20scan%20and%20a%20CZT%20myocardial%20SPECT%20%28DSPECT%2C%20Spectrum%20Dynamics%29%203%5Cu2009h%20after%20injection%20of%2099mTc-labeled%20bone%20tracer%20were%20analyzed.%20Visual%20scoring%20of%20cardiac%20retention%20was%20performed%20on%20whole-body%20scan%20according%20to%20Perugini%204-point%20grading%20system%20from%200%20%28no%20uptake%29%20to%203%20%28strong%20cardiac%20uptake%20with%20mild%5C%2Fabsent%20bone%20uptake%29.%20A%20planar%20heart-to-background%20%28H%3AB%29%20ratio%20was%20calculated%20using%20whole-body%20scan%20%28wb-H%3AB%29.%20CZT%20SPECT%20was%20quantified%20using%20three%20methods%3A%20planar%20H%3AB%20ratio%20calculated%20from%20anterior%20reprojection%20%28ant-H%3AB%29%2C%20left%20anterior%20oblique%20reprojection%20%28LAO-H%3AB%29%2C%20and%203D-H%3AB%20ratio%20calculated%20from%20transaxial%20slices%20as%20mean%20counts%20in%20a%20VOI%20encompassing%20the%20heart%20divided%20by%20background%20VOI%20in%20the%20contralateral%20lung.%20Interventricular%20septal%20thickness%20was%20obtained%20using%20echocardiography.%5CnRESULTS%3A%20H%3ABs%20obtained%20from%20planar%20and%20reprojected%20data%20were%20not%20statistically%20different%20%28wb-H%3AB%2C%202.05%5Cu2009%5Cu00b1%5Cu20090.64%2C%20ant-H%3AB%2C%201.97%5Cu2009%5Cu00b1%5Cu20090.61%2C%20LAO-H%3AB%2C%202.06%5Cu2009%5Cu00b1%5Cu20090.64%2C%20all%20p%5Cu2009%3D%5Cu2009ns%29.%20However%2C%203D-H%3AB%20was%20increased%20compared%20to%20planar%20H%3ABs%20%283D-H%3AB%2C%204.06%5Cu2009%5Cu00b1%5Cu20091.77%2C%20all%20p%5Cu2009%26lt%3B%5Cu20090.0001%20vs.%20wb-H%3AB%2C%20ant-H%3AB%2C%20and%20LAO-H%3AB%29.%20Bland-Altman%20plots%20demonstrated%20that%20the%20difference%20between%203D%20and%20planar%20H%3ABs%20increased%20with%20the%20mean%20value%20of%20myocardial%20uptake.%203D-H%3AB%20was%20best%20correlated%20to%20septal%20thickness%20%28r%5Cu2009%3D%5Cu20090.45%2C%20p%5Cu2009%26lt%3B%5Cu20090.001%29.%20Finally%2C%20abnormal%20right%20ventricular%20uptake%20was%20associated%20with%20higher%20values%20of%20cardiac%20retention.%5CnCONCLUSION%3A%203D%20semi-quantitative%20analysis%20of%20CZT%20SPECT%20optimized%20the%20assessment%20of%2099mTc-labeled%20bone%20tracer%20myocardial%20uptake%20in%20patients%20with%20cardiac%20amyloidosis.%22%2C%22date%22%3A%22Dec%2023%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13550-019-0584-8%22%2C%22ISSN%22%3A%222191-219X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22TEKQ9RWJ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Koffi%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKoffi%2C%20K.%20G.%2C%20D.%20A.%20Silu%26%23xE9%3B%2C%20C.%20Laurent%2C%20K.%20Boidy%2C%20S.%20Koui%2C%20G.%20Compaci%2C%20Z.%20H.%20Adeba%2C%20et%20al.%20%26%23x201C%3BAMAFRICA%2C%20a%20Patient-Navigator%20Program%20for%20Accompanying%20Lymphoma%20Patients%20during%20Chemotherapy%20in%20Ivory%20Coast%3A%20A%20Prospective%20Randomized%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2019%2C%20no.%201%20%28December%2023%2C%202019%29%3A%201247.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-6478-3%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-6478-3%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22AMAFRICA%2C%20a%20patient-navigator%20program%20for%20accompanying%20lymphoma%20patients%20during%20chemotherapy%20in%20Ivory%20Coast%3A%20a%20prospective%20randomized%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20G.%22%2C%22lastName%22%3A%22Koffi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20A.%22%2C%22lastName%22%3A%22Silu%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Boidy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Koui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Compaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%20H.%22%2C%22lastName%22%3A%22Adeba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Kamara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20P.%22%2C%22lastName%22%3A%22Botty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20S.%22%2C%22lastName%22%3A%22Bognini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Sanogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Despas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Laurent%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Previous%20studies%20have%20indicated%20that%20accompanying%20socially%20underserved%20cancer%20patients%20through%20Patient%20Navigator%20%28PN%29%20or%20PN-derived%20procedures%20improves%20therapy%20management%20and%20reassurance.%20At%20the%20Cancer%20Institute%20of%20Toulouse-Oncopole%20%28France%29%2C%20we%20have%20implemented%20AMA%20%28Ambulatory%20Medical%20Assistance%29%2C%20a%20PN-based%20procedure%20adapted%20for%20malignant%20lymphoma%20%28ML%29%20patients%20under%20therapy.%20We%20found%20that%20AMA%20improves%20adherence%20to%20chemotherapy%20and%20safety.%20In%20low-middle%20income%20countries%20%28LMIC%29%2C%20refusal%20and%20abandonment%20were%20documented%20as%20major%20adverse%20factors%20for%20cancer%20therapy.%20We%20reasoned%20that%20AMA%20could%20improve%20clinical%20management%20of%20ML%20patients%20in%20LMIC.%5CnMETHODS%3A%20This%20study%20was%20set%20up%20in%20the%20Abidjan%20University%20Medical%20Center%20%28Ivory%20Coast%29%20in%20collaboration%20with%20Toulouse.%20One%20hundred%20African%20patients%20were%20randomly%20assigned%20to%20either%20an%20AMA%20or%20control%20group.%20Main%20criteria%20of%20judgment%20were%20refusal%20and%20abandonment%20of%20CHOP%20or%20ABVD%20chemotherapy.%5CnRESULTS%3A%20We%20found%20that%20AMA%20was%20feasible%20and%20had%20significant%20impact%20on%20refusal%20and%20abandonment.%20However%2C%20only%20one%20third%20of%20patients%20completed%20their%20therapy%20in%20both%20groups.%20No%20differences%20were%20noted%20in%20terms%20of%20complete%20response%20rate%20%28CR%29%20%2816%25%20based%20on%20intent-to-treat%29%20and%20median%20overall%20survival%20%28OS%29%20%286%5Cu2009months%29.%20The%20main%20reason%20for%20refusal%20and%20abandonment%20was%20limitation%20of%20financial%20resources.%5CnCONCLUSION%3A%20Altogether%2C%20this%20study%20showed%20that%20PN%20may%20reduce%20refusal%20and%20abandonment%20of%20treatment.%20However%2C%20due%20to%20insufficient%20health%20care%20coverage%2C%20its%20ultimate%20impact%20on%20OS%20remains%20limited.%22%2C%22date%22%3A%22Dec%2023%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-019-6478-3%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22LWM8TDRT%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Garnache-Ottou%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGarnache-Ottou%2C%20Francine%2C%20Chrystelle%20Vidal%2C%20Sabeha%20Biichl%26%23xE9%3B%2C%20Florian%20Renosi%2C%20Eve%20Poret%2C%20Ma%26%23xEF%3Bder%20Pagadoy%2C%20Maxime%20Desmarets%2C%20et%20al.%20%26%23x201C%3BHow%20Should%20We%20Diagnose%20and%20Treat%20Blastic%20Plasmacytoid%20Dendritic%20Cell%20Neoplasm%20Patients%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BBlood%20Advances%26lt%3B%5C%2Fi%26gt%3B%203%2C%20no.%2024%20%28December%2023%2C%202019%29%3A%204238%26%23x2013%3B51.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2019000647%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2019000647%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20should%20we%20diagnose%20and%20treat%20blastic%20plasmacytoid%20dendritic%20cell%20neoplasm%20patients%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francine%22%2C%22lastName%22%3A%22Garnache-Ottou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chrystelle%22%2C%22lastName%22%3A%22Vidal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabeha%22%2C%22lastName%22%3A%22Biichl%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Renosi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eve%22%2C%22lastName%22%3A%22Poret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ma%5Cu00efder%22%2C%22lastName%22%3A%22Pagadoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Desmarets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Roggy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Seilles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lou%22%2C%22lastName%22%3A%22Soret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Schillinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Puyraimond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Petrella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Preudhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Roumier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%20A.%22%2C%22lastName%22%3A%22MacIntyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Harrivel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohan%22%2C%22lastName%22%3A%22Desbrosses%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9reng%5Cu00e8re%22%2C%22lastName%22%3A%22Gruson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Genevi%5Cu00e8ve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Thepot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuriy%22%2C%22lastName%22%3A%22Drebit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Leguay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois-Xavier%22%2C%22lastName%22%3A%22Gros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Lechevalier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Saussoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Salaun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Cornet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zehaira%22%2C%22lastName%22%3A%22Benseddik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Veyrat-Masson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Orianne%22%2C%22lastName%22%3A%22Wagner-Ballon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9lia%22%2C%22lastName%22%3A%22Salanoubat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Maynadi%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Guy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Caillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Jacob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Cahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Gressin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johann%22%2C%22lastName%22%3A%22Rose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Quesnel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Guerin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Trimoreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Feuillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Gourin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%22%2C%22lastName%22%3A%22Plesa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Baseggio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Arnoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Vey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Blaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romaric%22%2C%22lastName%22%3A%22Lacroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Arnoulet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blandine%22%2C%22lastName%22%3A%22Benet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Dorvaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Drenou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agathe%22%2C%22lastName%22%3A%22Debliquis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Latger-Cannard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bonmati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Bene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Peterlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Ticchioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Simon%22%2C%22lastName%22%3A%22Rohrlich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Arnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Wickenhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Bardet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Brechignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Papoular%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%22%2C%22lastName%22%3A%22Raggueneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Vargaftig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9mi%22%2C%22lastName%22%3A%22Letestu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Lusina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thorsten%22%2C%22lastName%22%3A%22Braun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Foissaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Tamburini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hind%22%2C%22lastName%22%3A%22Bennani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Freynet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Cordonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Le%20Garff-Tavernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Jacques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karim%22%2C%22lastName%22%3A%22Maloum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Roos-Weil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Bouscary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vahid%22%2C%22lastName%22%3A%22Asnafi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Lhermitte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%22%2C%22lastName%22%3A%22Suarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Lengline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22F%5Cu00e9ger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giorgia%22%2C%22lastName%22%3A%22Battipaglia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamad%22%2C%22lastName%22%3A%22Mohty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Bouyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ouda%22%2C%22lastName%22%3A%22Ghoual%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Dindinaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Basle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Puyade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carinne%22%2C%22lastName%22%3A%22Lafon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Fest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Roussel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Cahu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elsa%22%2C%22lastName%22%3A%22Bera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Daliphard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Jardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Campos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Solly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Guyotat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-C%5Cu00e9cile%22%2C%22lastName%22%3A%22Galoisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Eischen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Mayeur-Rousse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blandine%22%2C%22lastName%22%3A%22Guffroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Recher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Loosveld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Garnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Barlogis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Alessandra%22%2C%22lastName%22%3A%22Rosenthal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Brun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Contentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Maury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Callanan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lefebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Maillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Okamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Ferrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Adotevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Saas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Angelot-Delettre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Binda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Deconinck%22%7D%5D%2C%22abstractNote%22%3A%22Blastic%20plasmacytoid%20dendritic%20cell%20neoplasm%20%28BPDCN%29%20is%20a%20rare%20and%20aggressive%20leukemia%20for%20which%20we%20developed%20a%20nationwide%20network%20to%20collect%20data%20from%20new%20cases%20diagnosed%20in%20France.%20In%20a%20retrospective%2C%20observational%20study%20of%2086%20patients%20%282000-2013%29%2C%20we%20described%20clinical%20and%20biological%20data%20focusing%20on%20morphologies%20and%20immunophenotype.%20We%20found%20expression%20of%20markers%20associated%20with%20plasmacytoid%20dendritic%20cell%20origin%20%28HLA-DRhigh%2C%20CD303%2B%2C%20CD304%2B%2C%20and%20cTCL1%2B%29%20plus%20CD4%20and%20CD56%20and%20frequent%20expression%20of%20isolated%20markers%20from%20the%20myeloid%2C%20B-%2C%20and%20T-lymphoid%20lineages%2C%20whereas%20specific%20markers%20%28myeloperoxidase%2C%20CD14%2C%20cCD3%2C%20CD19%2C%20and%20cCD22%29%20were%20not%20expressed.%20Fifty-one%20percent%20of%20cytogenetic%20abnormalities%20impact%20chromosomes%2013%2C%2012%2C%209%2C%20and%2015.%20Myelemia%20was%20associated%20with%20an%20adverse%20prognosis.%20We%20categorized%20chemotherapeutic%20regimens%20into%205%20groups%3A%20acute%20myeloid%20leukemia%20%28AML%29-like%2C%20acute%20lymphoid%20leukemia%20%28ALL%29-like%2C%20lymphoma%20%28cyclophosphamide%2C%20doxorubicin%2C%20vincristine%2C%20and%20prednisone%20%5BCHOP%5D%29-like%2C%20high-dose%20methotrexate%20with%20asparaginase%20%28Aspa-MTX%29%20chemotherapies%2C%20and%20not%20otherwise%20specified%20%28NOS%29%20treatments.%20Thirty%20patients%20received%20allogeneic%20hematopoietic%20cell%20transplantation%20%28allo-HCT%29%2C%20and%204%20patients%20received%20autologous%20hematopoietic%20cell%20transplantation.%20There%20was%20no%20difference%20in%20survival%20between%20patients%20receiving%20AML-like%2C%20ALL-like%2C%20or%20Aspa-MTX%20regimens%3B%20survival%20was%20longer%20in%20patients%20who%20received%20AML-like%2C%20ALL-like%2C%20or%20Aspa-MTX%20regimens%20than%20in%20those%20who%20received%20CHOP-like%20regimens%20or%20NOS.%20Eleven%20patients%20are%20in%20persistent%20complete%20remission%20after%20allo-HCT%20with%20a%20median%20survival%20of%2049%20months%20vs%208%20for%20other%20patients.%20Our%20series%20confirms%20a%20high%20response%20rate%20with%20a%20lower%20toxicity%20profile%20with%20the%20Aspa-MTX%20regimen%2C%20offering%20the%20best%20chance%20of%20access%20to%20hematopoietic%20cell%20transplantation%20and%20a%20possible%20cure.%22%2C%22date%22%3A%22Dec%2023%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2019000647%22%2C%22ISSN%22%3A%222473-9537%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A52Z%22%7D%7D%2C%7B%22key%22%3A%2297LLVZVL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hofmann%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHofmann%2C%20Werner%2C%20Wei%20Bo%20Li%2C%20Werner%20Friedland%2C%20Brian%20W.%20Miller%2C%20Bal%26%23xE1%3Bzs%20Madas%2C%20Manuel%20Bardi%26%23xE8%3Bs%2C%20and%20Imre%20Bal%26%23xE1%3Bsh%26%23xE1%3Bzy.%20%26%23x201C%3BInternal%20Microdosimetry%20of%20Alpha-Emitting%20Radionuclides.%26%23x201D%3B%20%26lt%3Bi%26gt%3BRadiation%20and%20Environmental%20Biophysics%26lt%3B%5C%2Fi%26gt%3B%2C%20December%2021%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00411-019-00826-w%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00411-019-00826-w%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Internal%20microdosimetry%20of%20alpha-emitting%20radionuclides%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Werner%22%2C%22lastName%22%3A%22Hofmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wei%20Bo%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Werner%22%2C%22lastName%22%3A%22Friedland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%20W.%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bal%5Cu00e1zs%22%2C%22lastName%22%3A%22Madas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Bardi%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Imre%22%2C%22lastName%22%3A%22Bal%5Cu00e1sh%5Cu00e1zy%22%7D%5D%2C%22abstractNote%22%3A%22At%20the%20tissue%20level%2C%20energy%20deposition%20in%20cells%20is%20determined%20by%20the%20microdistribution%20of%20alpha-emitting%20radionuclides%20in%20relation%20to%20sensitive%20target%20cells.%20Furthermore%2C%20the%20highly%20localized%20energy%20deposition%20of%20alpha%20particle%20tracks%20and%20the%20limited%20range%20of%20alpha%20particles%20in%20tissue%20produce%20a%20highly%20inhomogeneous%20energy%20deposition%20in%20traversed%20cell%20nuclei.%20Thus%2C%20energy%20deposition%20in%20cell%20nuclei%20in%20a%20given%20tissue%20is%20characterized%20by%20the%20probability%20of%20alpha%20particle%20hits%20and%2C%20in%20the%20case%20of%20a%20hit%2C%20by%20the%20energy%20deposited%20there.%20In%20classical%20microdosimetry%2C%20the%20randomness%20of%20energy%20deposition%20in%20cellular%20sites%20is%20described%20by%20a%20stochastic%20quantity%2C%20the%20specific%20energy%2C%20which%20approximates%20the%20macroscopic%20dose%20for%20a%20sufficiently%20large%20number%20of%20energy%20deposition%20events.%20Typical%20examples%20of%20the%20alpha-emitting%20radionuclides%20in%20internal%20microdosimetry%20are%20radon%20progeny%20and%20plutonium%20in%20the%20lungs%2C%20plutonium%20and%20americium%20in%20bones%2C%20and%20radium%20in%20targeted%20radionuclide%20therapy.%20Several%20microdosimetric%20approaches%20have%20been%20proposed%20to%20relate%20specific%20energy%20distributions%20to%20radiobiological%20effects%2C%20such%20as%20hit-related%20concepts%2C%20LET%20and%20track%20length-based%20models%2C%20effect-specific%20interpretations%20of%20specific%20energy%20distributions%2C%20such%20as%20the%20dual%20radiation%20action%20theory%20or%20the%20hit-size%20effectiveness%20function%2C%20and%20finally%20track%20structure%20models.%20Since%20microdosimetry%20characterizes%20only%20the%20initial%20step%20of%20energy%20deposition%2C%20microdosimetric%20concepts%20are%20most%20successful%20in%20exposure%20situations%20where%20biological%20effects%20are%20dominated%20by%20energy%20deposition%2C%20but%20not%20by%20subsequently%20operating%20biological%20mechanisms.%20Indeed%2C%20the%20simulation%20of%20the%20combined%20action%20of%20physical%20and%20biological%20factors%20may%20eventually%20require%20the%20application%20of%20track%20structure%20models%20at%20the%20nanometer%20scale.%22%2C%22date%22%3A%22Dec%2021%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00411-019-00826-w%22%2C%22ISSN%22%3A%221432-2099%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22RGDMNNIG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zamora%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BZamora%2C%20Audrey%2C%20Melinda%20Alves%2C%20Charlotte%20Chollet%2C%20Nicole%20Therville%2C%20Tiffany%20Fougeray%2C%20Florence%20Tatin%2C%20Camille%20Franchet%2C%20et%20al.%20%26%23x201C%3BPaclitaxel%20Induces%20Lymphatic%20Endothelial%20Cells%20Autophagy%20to%20Promote%20Metastasis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCell%20Death%20%26amp%3B%20Disease%26lt%3B%5C%2Fi%26gt%3B%2010%2C%20no.%2012%20%28December%2020%2C%202019%29%3A%20956.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41419-019-2181-1%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41419-019-2181-1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Paclitaxel%20induces%20lymphatic%20endothelial%20cells%20autophagy%20to%20promote%20metastasis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Zamora%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melinda%22%2C%22lastName%22%3A%22Alves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Chollet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Therville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiffany%22%2C%22lastName%22%3A%22Fougeray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Tatin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Vaysse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%20O.%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Souad%22%2C%22lastName%22%3A%22Najib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Guillermet-Guibert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Lacazette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Catherine%22%2C%22lastName%22%3A%22Prats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Garmy-Susini%22%7D%5D%2C%22abstractNote%22%3A%22Cytotoxic%20therapy%20for%20breast%20cancer%20inhibits%20the%20growth%20of%20primary%20tumors%2C%20but%20promotes%20metastasis%20to%20the%20sentinel%20lymph%20nodes%20through%20the%20lymphatic%20system.%20However%2C%20the%20effect%20of%20first-line%20chemotherapy%20on%20the%20lymphatic%20endothelium%20has%20been%20poorly%20investigated.%20In%20this%20study%2C%20we%20determined%20that%20paclitaxel%2C%20the%20anti-cancer%20drug%20approved%20for%20the%20treatment%20of%20metastatic%20or%20locally%20advanced%20breast%20cancer%2C%20induces%20lymphatic%20endothelial%20cell%20%28LEC%29%20autophagy%20to%20increase%20metastases.%20While%20paclitaxel%20treatment%20was%20largely%20efficacious%20in%20inhibiting%20LEC%20adhesion%2C%20it%20had%20no%20effect%20on%20cell%20survival.%20Paclitaxel%20inhibited%20LEC%20migration%20and%20branch%20point%20formation%20by%20inducing%20an%20autophagy%20mechanism%20independent%20of%20Akt%20phosphorylation.%20In%20vivo%2C%20paclitaxel%20mediated%20a%20higher%20permeability%20of%20lymphatic%20endothelium%20to%20tumor%20cells%20and%20this%20effect%20was%20reversed%20by%20chloroquine%2C%20an%20autophagy-lysosome%20inhibitor.%20Despite%20a%20strong%20effect%20on%20reducing%20tumor%20size%2C%20paclitaxel%20significantly%20increased%20metastasis%20to%20the%20sentinel%20lymph%20nodes.%20This%20effect%20was%20restricted%20to%20a%20lymphatic%20dissemination%2C%20as%20chemotherapy%20did%20not%20affect%20the%20blood%20endothelium.%20Taken%20together%2C%20our%20findings%20suggest%20that%20the%20lymphatic%20system%20resists%20to%20chemotherapy%20through%20an%20autophagy%20mechanism%20to%20promote%20malignant%20progression%20and%20metastatic%20lesions.%20This%20study%20paves%20the%20way%20for%20new%20combinative%20therapies%20aimed%20at%20reducing%20the%20number%20of%20metastases.%22%2C%22date%22%3A%22Dec%2020%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41419-019-2181-1%22%2C%22ISSN%22%3A%222041-4889%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22PKLPPQDF%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22WUP5YQ33%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mass%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMass%26%23xE9%3B%2C%20Julie%2C%20Caroline%20Truntzer%2C%20Romain%20Boidot%2C%20Emmanuel%20Khalifa%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Val%26%23xE9%3Brie%20Velasco%2C%20La%26%23xE9%3Btitia%20Mayeur%2C%20et%20al.%20%26%23x201C%3BSolid-Type%20Adenoid%20Cystic%20Carcinoma%20of%20the%20Breast%2C%20a%20Distinct%20Molecular%20Entity%20Enriched%20in%20NOTCH%20and%20CREBBP%20Mutations.%26%23x201D%3B%20%26lt%3Bi%26gt%3BModern%20Pathology%3A%20An%20Official%20Journal%20of%20the%20United%20States%20and%20Canadian%20Academy%20of%20Pathology%2C%20Inc%26lt%3B%5C%2Fi%26gt%3B%2C%20December%2019%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-019-0425-3%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-019-0425-3%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Solid-type%20adenoid%20cystic%20carcinoma%20of%20the%20breast%2C%20a%20distinct%20molecular%20entity%20enriched%20in%20NOTCH%20and%20CREBBP%20mutations%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Mass%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Truntzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Boidot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Khalifa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Velasco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22La%5Cu00e9titia%22%2C%22lastName%22%3A%22Mayeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Billerey-Larmonier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Larry%22%2C%22lastName%22%3A%22Blanchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Charitansky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Soubeyran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Iggo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Arnould%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00ebtan%22%2C%22lastName%22%3A%22MacGrogan%22%7D%5D%2C%22abstractNote%22%3A%22Adenoid%20cystic%20carcinoma%20%28ACC%29%20of%20the%20breast%20with%20a%20predominant%20solid%20pattern%20is%20difficult%20to%20diagnose%20with%20certainty%20and%20differentiate%20from%20more%20common%20triple-negative%20breast%20cancers%20%28TNBCs%29%20of%20basal-phenotype.%20To%20better%20characterize%20solid%20ACC%2C%20we%20performed%20a%20clinical%2C%20morphological%2C%20immunohistochemical%2C%20and%20molecular%20comparative%20analysis%20of%2033%20ACCs%20of%20the%20breast%20comprising%2017%20solid%20variant%20ACCs%20and%2016%20conventional%20ACCs.%20Solid%20ACCs%20displayed%20basaloid%20morphology%20with%20an%20exclusive%20or%20predominant%20epithelial%20cell%20population%20associated%20with%20decreased%20myoepithelial%20differentiation%2C%20while%20demonstrating%20MYB%20protein%20overexpression%20similar%20to%20the%20more%20common%20type%20of%20ACC.%20Strong%20and%20diffuse%20MYB%20expression%20by%20immunochemistry%20was%20observed%20in%2014%5C%2F17%20%2882%25%29%20of%20solid%20ACCs%20while%20MYB%20rearrangements%20were%20detected%20by%20break%20apart%20fluorescence%20in%20situ%20hybridization%20%28FISH%29%20in%20only%203%5C%2F16%20%2819%25%29%20of%20solid%20ACCs.%20Conversely%2C%20weak%20MYB%20immunohistochemical%20expression%20was%20observed%20in%20only%207%5C%2F204%20%283%25%29%20of%20TNBC.%20Solid%20ACCs%20displayed%20a%20transcriptomic%20profile%20distinct%20from%20conventional%20ACCs%20with%20549%20genes%20showing%20a%20highly%20significant%20differential%20expression%20between%20conventional%20and%20solid%20ACC%20%5Bfalse%20discovery%20rate%20%28FDR%29%5Cu2009%26lt%3B%5Cu20090.01%3B%20log2FC%5Cu2009%26gt%3B%5Cu2009%7C1%7C%5D.%20EnrichR%20and%20Kegg%20Pathway%20analyses%20identified%20PI3K-Akt%20and%20focal%20adhesion%20signaling%20pathways%20as%20significantly%20overexpressed%20in%20conventional%20ACCs%20compared%20with%20solid%20ACCs%20which%20significantly%20overexpressed%20the%20nitrogen%20metabolism%20pathway.%20CREBBP%20mutations%20and%20NOTCH%20activating%20gene%20mutations%20were%20only%20present%20in%20solid%20ACCs%2C%20concerning%205%5C%2F16%20%2831%25%29%20of%20cases%20for%20each%20gene.%20Tumors%20with%20NOTCH%20activating%20mutations%20displayed%20a%20strong%20diffuse%20nuclear%20NICD1%20staining%2C%20an%20established%20marker%20of%20Notch%20pathway%20activation.%20Solid%20ACCs%20also%20differed%20from%20basal-type%20TNBC%2C%20with%20fewer%20TP53%20mutations%20and%20a%20more%20stable%20genomic%20profile%20on%20array%20comparative%20genomic%20hybridization%20%28CGH%29.%20In%20summary%2C%20solid-type%20ACC%20of%20the%20breast%20is%20a%20distinct%20molecular%20entity%20within%20the%20ACC%20family%20and%20is%20different%20from%20common%20basal-type%20TNBC.%20MYB%20is%20a%20diagnostically%20useful%20biomarker%20of%20solid%20ACC%20and%20NOTCH%20could%20be%20a%20novel%20potential%20therapeutic%20target%20in%2030%25%20of%20cases.%22%2C%22date%22%3A%22Dec%2019%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41379-019-0425-3%22%2C%22ISSN%22%3A%221530-0285%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22HULCNUZW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Franchet%20and%20Hoffmann%22%2C%22parsedDate%22%3A%222019-12-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFranchet%2C%20Camille%2C%20and%20Jean-S%26%23xE9%3Bbastien%20Hoffmann.%20%26%23x201C%3BWhen%20RAD52%20Allows%20Mitosis%20to%20Accept%20Unscheduled%20DNA%20Synthesis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%201%20%28December%2019%2C%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12010026%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12010026%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22When%20RAD52%20Allows%20Mitosis%20to%20Accept%20Unscheduled%20DNA%20Synthesis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Hoffmann%22%7D%5D%2C%22abstractNote%22%3A%22Faithful%20duplication%20of%20the%20human%20genome%20during%20the%20S%20phase%20of%20cell%20cycle%20and%20accurate%20segregation%20of%20sister%20chromatids%20in%20mitosis%20are%20essential%20for%20the%20maintenance%20of%20chromosome%20stability%20from%20one%20generation%20of%20cells%20to%20the%20next.%20Cells%20that%20are%20copying%20their%20DNA%20in%20preparation%20for%20division%20can%20suffer%20from%20%26%23039%3Breplication%20stress%26%23039%3B%20%28RS%29%20due%20to%20various%20external%20or%20endogenous%20impediments%20that%20slow%20or%20stall%20replication%20forks.%20RS%20is%20a%20major%20cause%20of%20pathologies%20including%20cancer%2C%20premature%20ageing%20and%20other%20disorders%20associated%20with%20genomic%20instability.%20It%20particularly%20affects%20genomic%20loci%20where%20progression%20of%20replication%20forks%20is%20intrinsically%20slow%20or%20problematic%2C%20such%20as%20common%20fragile%20site%20%28CFS%29%2C%20telomeres%2C%20and%20repetitive%20sequences.%20Although%20the%20eukaryotic%20cell%20cycle%20is%20conventionally%20thought%20of%20as%20several%20separate%20steps%2C%20each%20of%20which%20must%20be%20completed%20before%20the%20next%20one%20is%20initiated%2C%20it%20is%20now%20accepted%20that%20incompletely%20replicated%20chromosomal%20domains%20generated%20in%20S%20phase%20upon%20RS%20at%20these%20genomic%20loci%20can%20result%20in%20late%20DNA%20synthesis%20in%20G2%5C%2FM.%20In%202013%2C%20during%20investigations%20into%20the%20mechanism%20by%20which%20the%20specialized%20DNA%20polymerase%20eta%20%28Pol%20%5Cu03b7%29%20contributes%20to%20the%20replication%20and%20stability%20of%20CFS%2C%20we%20unveiled%20that%20indeed%20some%20DNA%20synthesis%20was%20still%20occurring%20in%20early%20mitosis%20at%20these%20loci.%20This%20surprising%20observation%20of%20mitotic%20DNA%20synthesis%20that%20differs%20fundamentally%20from%20canonical%20semi-conservative%20DNA%20replication%20in%20S-phase%20has%20been%20then%20confirmed%2C%20called%20%26quot%3BMiDAS%26quot%3Band%20believed%20to%20counteract%20potentially%20lethal%20chromosome%20mis-segregation%20and%20non-disjunction.%20While%20other%20contributions%20in%20this%20Special%20Issue%20of%20Cancers%20focus%20on%20the%20role%20of%20RAS52RAD52%20during%20MiDAS%2C%20this%20review%20emphases%20on%20the%20discovery%20of%20MiDAS%20and%20its%20molecular%20effectors.%22%2C%22date%22%3A%22Dec%2019%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12010026%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A53Z%22%7D%7D%2C%7B%22key%22%3A%228J72VAHC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Meyrignac%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-18%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMeyrignac%2C%20Olivier%2C%20%26%23xC9%3Blise%20Arcis%2C%20Marie-Charlotte%20Delchier%2C%20Fatima-Zohra%20Mokrane%2C%20Jean%20Darcourt%2C%20Herv%26%23xE9%3B%20Rousseau%2C%20and%20B%26%23xE9%3Batrice%20Bouhanick.%20%26%23x201C%3BImpact%20of%20Cone%20Beam%20-%20CT%20on%20Adrenal%20Vein%20Sampling%20in%20Primary%20Aldosteronism.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Radiology%26lt%3B%5C%2Fi%26gt%3B%20124%20%28December%2018%2C%202019%29%3A%20108792.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejrad.2019.108792%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejrad.2019.108792%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20cone%20beam%20-%20CT%20on%20adrenal%20vein%20sampling%20in%20primary%20aldosteronism%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Meyrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9lise%22%2C%22lastName%22%3A%22Arcis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Charlotte%22%2C%22lastName%22%3A%22Delchier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima-Zohra%22%2C%22lastName%22%3A%22Mokrane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Darcourt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9atrice%22%2C%22lastName%22%3A%22Bouhanick%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20The%20aim%20of%20this%20study%20in%20a%20group%20of%20patients%20with%20primary%20aldosteronism%20was%20to%20evaluate%20the%20contribution%20of%20CB-CT%20%28cone%20beam%20CT%29%20to%20the%20overall%20success%20rate%20of%20adrenal%20vein%20sampling%20%28AVS%29%2C%20and%20in%20particular%20to%20the%20selective%20cannulation%20of%20the%20right%20adrenal%20vein%20%28RAV%29.%5CnMETHOD%3A%20This%20was%20a%20retrospective%20single-center%20study%20including%2091%20AVS%20procedures%20performed%20by%20our%20consultant%20radiologist%20between%20March%202011%20and%20January%202017.%20Fifty%20cases%20were%20performed%20with%20CB-CT%20and%2050%20were%20performed%20without.%20Angiography%20with%20CB-CT%20was%20carried%20out%20after%20RAV%20cannulation%20to%20check%20the%20accurate%20catheter%20position.%20For%20each%20patient%2C%20we%20collected%20technical%20and%20biochemical%20success%20rates%2C%20as%20well%20as%20irradiation%20data.%5CnRESULTS%3A%20The%20overall%20success%20rate%20of%20AVS%20with%20CB-CT%20was%2080%20%25%2C%20vs.%2044%20%25%20without%20%28p%5Cu2009%3D%5Cu20090.00046%29%2C%20with%20right-sided%20selectivity%20of%2088%20%25%20vs.%2049%20%25%20%28p%5Cu2009%26lt%3B%5Cu20090.0001%29.%20There%20was%20no%20significant%20increase%20in%20radiation%20exposure%20with%20CB-CT%20%28p%5Cu2009%3D%5Cu20090.8206%29.%20Fluoroscopy%20time%20and%20quantity%20of%20iodine%20injected%20were%20significantly%20lower%20with%20CB-CT%20than%20without%20%28p%5Cu2009%3D%5Cu20090.0039%20and%20p%5Cu2009%26lt%3B%5Cu20090.0001%29.%5CnCONCLUSION%3A%20CB-CT%20allows%20a%20better%20evaluation%20of%20the%20selectivity%20of%20right-sided%20adrenal%20catheterization%20and%20greatly%20increases%20the%20overall%20success%20rate%20of%20AVS.%22%2C%22date%22%3A%22Dec%2018%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejrad.2019.108792%22%2C%22ISSN%22%3A%221872-7727%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22TE2VLRVY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Appay%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAppay%2C%20Romain%2C%20Caroline%20Dehais%2C%20Claude-Alain%20Maurage%2C%20Agusti%20Alentorn%2C%20Catherine%20Carpentier%2C%20Carole%20Colin%2C%20Fran%26%23xE7%3Bois%20Ducray%2C%20et%20al.%20%26%23x201C%3BCDKN2A%20Homozygous%20Deletion%20Is%20a%20Strong%20Adverse%20Prognosis%20Factor%20in%20Diffuse%20Malignant%20IDH-Mutant%20Gliomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeuro-Oncology%26lt%3B%5C%2Fi%26gt%3B%2021%2C%20no.%2012%20%28December%2017%2C%202019%29%3A%201519%26%23x2013%3B28.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fneuonc%5C%2Fnoz124%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fneuonc%5C%2Fnoz124%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CDKN2A%20homozygous%20deletion%20is%20a%20strong%20adverse%20prognosis%20factor%20in%20diffuse%20malignant%20IDH-mutant%20gliomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Appay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dehais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude-Alain%22%2C%22lastName%22%3A%22Maurage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agusti%22%2C%22lastName%22%3A%22Alentorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Carpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Colin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Ducray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Escande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Idbaih%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Kamoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22Marie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karima%22%2C%22lastName%22%3A%22Mokhtari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Tabouret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nesrine%22%2C%22lastName%22%3A%22Trabelsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Delattre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22POLA%20Network%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%202016%20World%20Health%20Organization%20%28WHO%29%20classification%20of%20central%20nervous%20system%20tumors%20stratifies%20isocitrate%20dehydrogenase%20%28IDH%29-mutant%20gliomas%20into%202%20major%20groups%20depending%20on%20the%20presence%20or%20absence%20of%201p%5C%2F19q%20codeletion.%20However%2C%20the%20grading%20system%20remains%20unchanged%20and%20it%20is%20now%20controversial%20whether%20it%20can%20be%20still%20applied%20to%20this%20updated%20molecular%20classification.%5CnMETHODS%3A%20In%20a%20large%20cohort%20of%20911%20high-grade%20IDH-mutant%20gliomas%20from%20the%20French%20national%20POLA%20network%20%28including%20428%20IDH-mutant%20gliomas%20without%201p%5C%2F19q%20codeletion%20and%20483%20anaplastic%20oligodendrogliomas%2C%20IDH-mutant%20and%201p%5C%2F19q%20codeleted%29%2C%20we%20investigated%20the%20prognostic%20value%20of%20the%20cyclin-dependent%20kinase%20inhibitor%202A%20%28CDKN2A%29%20gene%20homozygous%20deletion%20as%20well%20as%20WHO%20grading%20criteria%20%28mitoses%2C%20microvascular%20proliferation%2C%20and%20necrosis%29.%20In%20addition%2C%20we%20searched%20for%20other%20retinoblastoma%20pathway%20gene%20alterations%20%28CDK4%20amplification%20and%20RB1%20homozygous%20deletion%29%20in%20a%20subset%20of%20patients.%20CDKN2A%20homozygous%20deletion%20was%20also%20searched%20in%20an%20independent%20series%20of%2040%20grade%20II%20IDH-mutant%20gliomas.%5CnRESULTS%3A%20CDKN2A%20homozygous%20deletion%20was%20associated%20with%20dismal%20outcome%20among%20IDH-mutant%20gliomas%20lacking%201p%5C%2F19q%20codeletion%20%28P%20%26lt%3B%200.0001%20for%20progression-free%20survival%20and%20P%20%3D%200.004%20for%20overall%20survival%29%20as%20well%20as%20among%20anaplastic%20oligodendrogliomas%2C%20IDH-mutant%20%2B%201p%5C%2F19q%20codeleted%20%28P%20%3D%200.002%20for%20progression-free%20survival%20and%20P%20%26lt%3B%200.0001%20for%20overall%20survival%29%20in%20univariate%20and%20multivariate%20analysis%20including%20age%2C%20extent%20of%20surgery%2C%20adjuvant%20treatment%2C%20microvascular%20proliferation%2C%20and%20necrosis.%20In%20both%20groups%2C%20the%20presence%20of%20microvascular%20proliferation%20and%5C%2For%20necrosis%20remained%20of%20prognostic%20value%20only%20in%20cases%20lacking%20CDKN2A%20homozygous%20deletion.%20CDKN2A%20homozygous%20deletion%20was%20not%20recorded%20in%20grade%20II%20gliomas.%5CnCONCLUSIONS%3A%20Our%20study%20pointed%20out%20the%20utmost%20relevance%20of%20CDKN2A%20homozygous%20deletion%20as%20an%20adverse%20prognostic%20factor%20in%20the%202%20broad%20categories%20of%20IDH-mutant%20gliomas%20stratified%20on%201p%5C%2F19q%20codeletion%20and%20suggests%20that%20the%20grading%20of%20these%20tumors%20should%20be%20refined.%22%2C%22date%22%3A%22Dec%2017%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fneuonc%5C%2Fnoz124%22%2C%22ISSN%22%3A%221523-5866%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22363SEM5W%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mazerolle%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMazerolle%2C%20P.%2C%20T.%20Meresse%2C%20D.%20Gangloff%2C%20K.%20Kolsi%2C%20and%20A.%20Dupret-Bories.%20%26%23x201C%3BVascularized%20Lymph%20Node%20Transfer%20with%20Submental%20Free%20Flap.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Annals%20of%20Otorhinolaryngology%2C%20Head%20and%20Neck%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2C%20December%2016%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.anorl.2019.11.004%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.anorl.2019.11.004%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Vascularized%20lymph%20node%20transfer%20with%20submental%20free%20flap%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Mazerolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Meresse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Gangloff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Kolsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dupret-Bories%22%7D%5D%2C%22abstractNote%22%3A%22Limb%20lymphoedema%20is%20common%20in%20patients%20who%20have%20undergone%20inguinal%20or%20axillary%20lymph%20node%20dissection.%20Lymphoedema%20seriously%20impacts%20the%20patient%26%23039%3Bs%20quality%20of%20life%20by%20inducing%20adipogenesis%2C%20fibrosis%20and%20repeated%20episodes%20of%20lymphangitis%20and%20cellulitis.%20Following%20failure%20of%20compression%20therapies%2C%20several%20curative%20or%20symptomatic%20surgical%20options%20have%20been%20proposed%20over%20recent%20decades%2C%20such%20as%20liposuction%20or%20lymphovenous%20anastomosis.%20Vascularized%20lymph%20node%20transfer%20techniques%20have%20recently%20been%20described%2C%20with%20promising%20results.%20Vascularized%20lymph%20node%20transfer%20with%20submental%20free%20flap%20appears%20to%20be%20the%20most%20reliable%20of%20these%20technique%2C%20associated%20with%20the%20lowest%20morbidity.%20The%20flap%20harvesting%20technique%20presents%20several%20specific%20differences%20compared%20to%20conventional%20submental%20free%20flap.%20A%20good%20knowledge%20of%20neck%20anatomy%20is%20essential%20and%20multimodal%20and%20multidisciplinary%20management%20is%20often%20required.%20In%20the%20light%20of%20a%20case%20report%2C%20we%20describe%20the%20basic%20submental%20free%20flap%20technique%20for%20vascularized%20lymph%20node%20transfer%20for%20the%20treatment%20of%20lower%20limb%20lymphoedema.%20This%20technique%20may%20be%20used%20by%20head%20and%20neck%20surgeons%20performing%20flap%20harvest%2C%20as%20well%20as%20plastic%20surgeon%20surgeons%20or%20gynaecologists%20ensuring%20long-term%20management%20of%20these%20patients.%22%2C%22date%22%3A%22Dec%2016%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.anorl.2019.11.004%22%2C%22ISSN%22%3A%221879-730X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22Q82A778M%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ploussard%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPloussard%2C%20Guillaume%2C%20C%26%23xE9%3Bcile%20Manceau%2C%20Jean-Baptiste%20Beauval%2C%20Marine%20Lesourd%2C%20Christophe%20Almeras%2C%20Jean-Romain%20Gautier%2C%20Guillaume%20Loison%2C%20et%20al.%20%26%23x201C%3BDecreased%20Accuracy%20of%20the%20Prostate%20Cancer%20EAU%20Risk%20Group%20Classification%20in%20the%20Era%20of%20Imaging-Guided%20Diagnostic%20Pathway%3A%20Proposal%20for%20a%20New%20Classification%20Based%20on%20MRI-Targeted%20Biopsies%20and%20Early%20Oncologic%20Outcomes%20after%20Surgery.%26%23x201D%3B%20%26lt%3Bi%26gt%3BWorld%20Journal%20of%20Urology%26lt%3B%5C%2Fi%26gt%3B%2C%20December%2014%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00345-019-03053-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00345-019-03053-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Decreased%20accuracy%20of%20the%20prostate%20cancer%20EAU%20risk%20group%20classification%20in%20the%20era%20of%20imaging-guided%20diagnostic%20pathway%3A%20proposal%20for%20a%20new%20classification%20based%20on%20MRI-targeted%20biopsies%20and%20early%20oncologic%20outcomes%20after%20surgery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Ploussard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Manceau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Beauval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Lesourd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Almeras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Romain%22%2C%22lastName%22%3A%22Gautier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Loison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambroise%22%2C%22lastName%22%3A%22Salin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Souli%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Tollon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Malavaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Roumigui%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20To%20assess%20the%20performance%20of%20EAU%20risk%20classification%20in%20PCa%20patients%20according%20to%20the%20biopsy%20pathway%20%28standard%20versus%20MRI%20guided%29%20and%20to%20develop%20a%20new%2C%20more%20accurate%2C%20targeted%20biopsy%20%28TB%29-based%20classification.%5CnMATERIALS%20AND%20METHODS%3A%20We%20included%201345%20patients%20consecutively%20operated%20by%20radical%20prostatectomy%20%28RP%29%20since%202014%2C%20when%20MRI%20and%20TB%20were%20introduced%20in%20the%20diagnostic%20pathway.%20Patients%20underwent%20systematic%20biopsy%20%28SB%29%20only%20%28n%5Cu2009%3D%5Cu2009819%29%20or%20SB%20and%20TB%20%28n%5Cu2009%3D%5Cu2009526%29%20prior%20to%20RP%20during%20the%20same%20time%20period.%20Pathological%20and%20biochemical%20outcomes%20were%20compared%20between%20PCa%20men%20undergoing%20SB%20%28SB%20cohort%29%20and%20a%20combination%20of%20TB%20and%20SB%20%28TB%20cohort%29.%20Kaplan-Meier%20and%20Cox%20regression%20models%20were%20used%20to%20assess%20biochemical%20recurrence-free%20survival%20%28RFS%29.%5CnRESULTS%3A%20Both%20cohorts%20were%20comparable%20regarding%20final%20pathology%20and%20RFS%20%28p%5Cu2009%3D%5Cu20090.538%29.%20The%20EAU%20risk%20classification%20accurately%20predicted%20outcomes%20in%20SB%20cohort%2C%20but%20did%20not%20significantly%20separate%20low%20from%20intermediate%20risk%20in%20TB%20cohort%20%28p%5Cu2009%3D%5Cu20090.791%29.%20In%20TB%20cohort%2C%20the%20new%20proposed%20three-group%20risk%20classification%20significantly%20improved%20the%20recurrence%20risk%20prediction%20compared%20with%20the%20EAU%20risk%20classification%3A%20HR%204%20%28versus%20HR%201.2%2C%20p%5Cu2009%3D%5Cu20090.009%29%20for%20intermediate%2C%20and%20HR%2015%20%28versus%20HR%206.5%2C%20p%5Cu2009%26lt%3B%5Cu20090.001%29%20in%20high-risk%20groups%2C%20respectively.%20A%20fourth%20group%20defining%20very%20high-risk%20cases%20%28%5Cu2265%5Cu00a0T2c%20clinical%20stage%20or%20grade%20group%205%29%20was%20also%20proposed.%5CnCONCLUSIONS%3A%20The%20new%20classification%20integrating%20TB%20findings%20we%20propose%20meaningfully%20improves%20the%20recurrence%20prediction%20after%20surgery%20in%20patients%20undergoing%20a%20TB-based%20diagnostic%20pathway%2C%20compared%20with%20standard%20EAU%20risk%20classification%20which%20is%20still%20relevant%20for%20patients%20undergoing%20only%20SB.%20External%20validation%20is%20needed.%22%2C%22date%22%3A%22Dec%2014%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00345-019-03053-6%22%2C%22ISSN%22%3A%221433-8726%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22D5T794KM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Frigeni%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFrigeni%2C%20Marco%2C%20Caroline%20Besson%2C%20Carlo%20Visco%2C%20Helene%20Fontaine%2C%20Maria%20Goldaniga%2C%20Marcella%20Visentini%2C%20Alessandro%20Pulsoni%2C%20et%20al.%20%26%23x201C%3BInterferon-Free%20Compared%20to%20Interferon-Based%20Antiviral%26%23xA0%3BRegimens%20as%20First-Line%20Therapy%20for%20B-Cell%20Lymphoproliferative%20Disorders%20Associated%20with%20Hepatitis%20C%20Virus%20Infection.%26%23x201D%3B%20%26lt%3Bi%26gt%3BLeukemia%26lt%3B%5C%2Fi%26gt%3B%2C%20December%2013%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-019-0687-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-019-0687-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Interferon-free%20compared%20to%20interferon-based%20antiviral%5Cu00a0regimens%20as%20first-line%20therapy%20for%20B-cell%20lymphoproliferative%20disorders%20associated%20with%20hepatitis%20C%20virus%20infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Frigeni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Besson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Visco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Fontaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Goldaniga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcella%22%2C%22lastName%22%3A%22Visentini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Pulsoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harrys%20A.%22%2C%22lastName%22%3A%22Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Peveling-Oberhag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Rossotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Zaja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luigi%22%2C%22lastName%22%3A%22Rigacci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michele%22%2C%22lastName%22%3A%22Merli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Dorival%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Alric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Piazza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Massimo%22%2C%22lastName%22%3A%22Gentile%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Ferrari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Pirisi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luca%22%2C%22lastName%22%3A%22Nassi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Rattotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annamaria%22%2C%22lastName%22%3A%22Frustaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michele%22%2C%22lastName%22%3A%22Milella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuele%22%2C%22lastName%22%3A%22Cencini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%22%2C%22lastName%22%3A%22Defrancesco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginia%20Valeria%22%2C%22lastName%22%3A%22Ferretti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raffaele%22%2C%22lastName%22%3A%22Bruno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Hermine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luca%22%2C%22lastName%22%3A%22Arcaini%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Dec%2013%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41375-019-0687-2%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22NEM5X4BU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hantelys%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHantelys%2C%20Fransky%2C%20Anne-Claire%20Godet%2C%20Florian%20David%2C%20Florence%20Tatin%2C%20Edith%20Renaud-Gabardos%2C%20Fran%26%23xE7%3Boise%20Pujol%2C%20Leila%20H.%20Diallo%2C%20et%20al.%20%26%23x201C%3BVasohibin1%2C%20a%20New%20Mouse%20Cardiomyocyte%20IRES%20Trans-Acting%20Factor%20That%20Regulates%20Translation%20during%20Early%20Hypoxia.%26%23x201D%3B%20%26lt%3Bi%26gt%3BeLife%26lt%3B%5C%2Fi%26gt%3B%208%20%28December%209%2C%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7554%5C%2FeLife.50094%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7554%5C%2FeLife.50094%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Vasohibin1%2C%20a%20new%20mouse%20cardiomyocyte%20IRES%20trans-acting%20factor%20that%20regulates%20translation%20during%20early%20hypoxia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fransky%22%2C%22lastName%22%3A%22Hantelys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Claire%22%2C%22lastName%22%3A%22Godet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22David%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Tatin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%22%2C%22lastName%22%3A%22Renaud-Gabardos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Pujol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%20H.%22%2C%22lastName%22%3A%22Diallo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Ader%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ligat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20K.%22%2C%22lastName%22%3A%22Henras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasufumi%22%2C%22lastName%22%3A%22Sato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelo%22%2C%22lastName%22%3A%22Parini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Lacazette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Garmy-Susini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Catherine%22%2C%22lastName%22%3A%22Prats%22%7D%5D%2C%22abstractNote%22%3A%22Hypoxia%2C%20a%20major%20inducer%20of%20angiogenesis%2C%20triggers%20major%20changes%20of%20gene%20expression%20at%20the%20transcriptional%20level.%20Furthermore%2C%20global%20protein%20synthesis%20is%20blocked%20while%20internal%20ribosome%20entry%20sites%20%28IRES%29%20allow%20specific%20mRNAs%20to%20be%20translated.%20Here%20we%20report%20the%20transcriptome%20and%20translatome%20signatures%20of%20%28lymph%29angiogenic%20genes%20in%20hypoxic%20HL-1%20mouse%20cardiomyocytes%3A%20most%20genes%20are%20induced%20at%20the%20translatome%20level%2C%20including%20all%20IRES-containing%20mRNAs.%20Our%20data%20reveal%20activation%20of%20%28lymph%29angiogenic%20factor%20mRNA%20IRESs%20in%20early%20hypoxia.%20We%20identify%20vasohibin1%20%28VASH1%29%20as%20an%20IRES%20trans-acting%20factor%20%28ITAF%29%20able%20to%20bind%20RNA%20and%20to%20activate%20the%20FGF1%20IRES%20in%20hypoxia%20while%20it%20tends%20to%20inhibit%20several%20IRESs%20in%20normoxia.%20VASH1%20depletion%20has%20also%20a%20wide%20impact%20on%20the%20translatome%20of%20%28lymph%29angiogenesis%20genes%2C%20suggesting%20that%20this%20protein%20can%20regulate%20translation%20positively%20or%20negatively%20in%20early%20hypoxia.%20Translational%20control%20thus%20appears%20as%20a%20pivotal%20process%20to%20trigger%20new%20vessel%20formation%20in%20ischemic%20heart.%22%2C%22date%22%3A%22Dec%2009%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7554%5C%2FeLife.50094%22%2C%22ISSN%22%3A%222050-084X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22EZST2VFL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tang%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTang%2C%20Nicolas%2C%20Marta%20Bueno%2C%20Sylvain%20Meylan%2C%20Yann%20Perrot%2C%20Hoang%20N.%20Tran%2C%20Am%26%23xE9%3Blie%20Freneau%2C%20Morgane%20Dos%20Santos%2C%20et%20al.%20%26%23x201C%3BAssessment%20of%20Radio-Induced%20Damage%20in%20Endothelial%20Cells%20Irradiated%20with%2040%20kVp%2C%20220%20kVp%2C%20and%204%20MV%20X-Rays%20by%20Means%20of%20Micro%20and%20Nanodosimetric%20Calculations.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Molecular%20Sciences%26lt%3B%5C%2Fi%26gt%3B%2020%2C%20no.%2024%20%28December%209%2C%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms20246204%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms20246204%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessment%20of%20Radio-Induced%20Damage%20in%20Endothelial%20Cells%20Irradiated%20with%2040%20kVp%2C%20220%20kVp%2C%20and%204%20MV%20X-rays%20by%20Means%20of%20Micro%20and%20Nanodosimetric%20Calculations%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Tang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Bueno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Meylan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Perrot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hoang%20N.%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Freneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Vaurijoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00ebtan%22%2C%22lastName%22%3A%22Gruel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%20A.%22%2C%22lastName%22%3A%22Bernal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Claude%22%2C%22lastName%22%3A%22Bordage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitris%22%2C%22lastName%22%3A%22Emfietzoglou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ziad%22%2C%22lastName%22%3A%22Francis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susanna%22%2C%22lastName%22%3A%22Guatelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22Ivanchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Karamitros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioanna%22%2C%22lastName%22%3A%22Kyriakou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wook-Geun%22%2C%22lastName%22%3A%22Shin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Incerti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Villagrasa%22%7D%5D%2C%22abstractNote%22%3A%22The%20objective%20of%20this%20work%20was%20to%20study%20the%20differences%20in%20terms%20of%20early%20biological%20effects%20that%20might%20exist%20between%20different%20X-rays%20energies%20by%20using%20a%20mechanistic%20approach.%20To%20this%20end%2C%20radiobiological%20experiments%20exposing%20cell%20monolayers%20to%20three%20X-ray%20energies%20were%20performed%20in%20order%20to%20assess%20the%20yields%20of%20early%20DNA%20damage%2C%20in%20particular%20of%20double-strand%20breaks%20%28DSBs%29.%20The%20simulation%20of%20these%20irradiations%20was%20set%20in%20order%20to%20understand%20the%20differences%20in%20the%20obtained%20experimental%20results.%20Hence%2C%20simulated%20results%20in%20terms%20of%20microdosimetric%20spectra%20and%20early%20DSB%20induction%20were%20analyzed%20and%20compared%20to%20the%20experimental%20data.%20Human%20umbilical%20vein%20endothelial%20cells%20%28HUVECs%29%20were%20irradiated%20with%2040%2C%20220%20kVp%2C%20and%204%20MV%20X-rays.%20The%20Geant4%20Monte%20Carlo%20simulation%20toolkit%20and%20its%20extension%20Geant4-DNA%20were%20used%20for%20the%20simulations.%20Microdosimetric%20calculations%20aiming%20to%20determine%20possible%20differences%20in%20the%20variability%20of%20the%20energy%20absorbed%20by%20the%20irradiated%20cell%20population%20for%20those%20photon%20spectra%20were%20performed%20on%2010%2C000%20endothelial%20cell%20nuclei%20representing%20a%20cell%20monolayer.%20Nanodosimetric%20simulations%20were%20also%20carried%20out%20using%20a%20computation%20chain%20that%20allowed%20the%20simulation%20of%20physical%2C%20physico-chemical%2C%20and%20chemical%20stages%20on%20a%20single%20realistic%20endothelial%20cell%20nucleus%20model%20including%20both%20heterochromatin%20and%20euchromatin.%20DNA%20damage%20was%20scored%20in%20terms%20of%20yields%20of%20prompt%20DSBs%20per%20Gray%20%28Gy%29%20and%20per%20giga%20%28109%29%20base%20pair%20%28Gbp%29%20and%20DSB%20complexity%20was%20derived%20in%20order%20to%20be%20compared%20to%20experimental%20data%20expressed%20as%20numbers%20of%20histone%20variant%20H2AX%20%28%5Cu03b3-H2AX%29%20foci%20per%20cell.%20The%20calculated%20microdosimetric%20spread%20in%20the%20irradiated%20cell%20population%20was%20similar%20when%20comparing%20between%2040%20and%20220%20kVp%20X-rays%20and%20higher%20when%20comparing%20with%204%20MV%20X-rays.%20Simulated%20yields%20of%20induced%20DSB%5C%2FGy%5C%2FGbp%20were%20found%20to%20be%20equivalent%20to%20those%20for%2040%20and%20220%20kVp%20but%20larger%20than%20those%20for%204%20MV%2C%20resulting%20in%20a%20relative%20biological%20effectiveness%20%28RBE%29%20of%201.3.%20Additionally%2C%20DSB%20complexity%20was%20similar%20between%20the%20considered%20photon%20spectra.%20Simulated%20results%20were%20in%20good%20agreement%20with%20experimental%20data%20obtained%20by%20IRSN%20%28Institut%20de%20radioprotection%20et%20de%20s%5Cu00fbret%5Cu00e9%20nucl%5Cu00e9aire%29%20radiobiologists.%20Despite%20differences%20in%20photon%20energy%2C%20few%20differences%20were%20observed%20when%20comparing%20between%2040%20and%20220%20kVp%20X-rays%20in%20microdosimetric%20and%20nanodosimetric%20calculations.%20Nevertheless%2C%20variations%20were%20observed%20when%20comparing%20between%2040%5C%2F220%20kVp%20and%204%20MV%20X-rays.%20Thanks%20to%20the%20simulation%20results%2C%20these%20variations%20were%20able%20to%20be%20explained%20by%20the%20differences%20in%20the%20production%20of%20secondary%20electrons%20with%20energies%20below%2010%20keV.%22%2C%22date%22%3A%22Dec%2009%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fijms20246204%22%2C%22ISSN%22%3A%221422-0067%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22XZPZPTJ6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22P%5Cu00e9ricart%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BP%26%23xE9%3Bricart%2C%20Sarah%2C%20Charlotte%20Waysse%2C%20Aurore%20Siegfried%2C%20Stephanie%20Struski%2C%20Eric%20Delabesse%2C%20Camille%20Laurent%2C%20and%20Sol%26%23xE8%3Bne%20Evrard.%20%26%23x201C%3BSubsequent%20Development%20of%20Histiocytic%20Sarcoma%20and%20Follicular%20Lymphoma%3A%20Cytogenetics%20and%20next-Generation%20Sequencing%20Analyses%20Provide%20Evidence%20for%20Transdifferentiation%20of%20Early%20Common%20Lymphoid%20Precursor-a%20Case%20Report%20and%20Review%20of%20Literature.%26%23x201D%3B%20%26lt%3Bi%26gt%3BVirchows%20Archiv%3A%20An%20International%20Journal%20of%20Pathology%26lt%3B%5C%2Fi%26gt%3B%2C%20December%205%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-019-02691-w%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-019-02691-w%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Subsequent%20development%20of%20histiocytic%20sarcoma%20and%20follicular%20lymphoma%3A%20cytogenetics%20and%20next-generation%20sequencing%20analyses%20provide%20evidence%20for%20transdifferentiation%20of%20early%20common%20lymphoid%20precursor-a%20case%20report%20and%20review%20of%20literature%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Waysse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Struski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Evrard%22%7D%5D%2C%22abstractNote%22%3A%22Histiocytic%20sarcoma%20%28HS%29%20is%20a%20rare%20aggressive%20hematologic%20neoplasm%20that%20can%20be%20associated%20with%20low-grade%20B%20cell%20lymphoma.%20The%20development%20of%20both%20neoplasms%20is%20currently%20being%20considered%20a%20transdifferentiation%20mechanism%20but%20remains%20elusive.%20We%20report%20the%20case%20of%20a%2065-year-old%20patient%20with%20synchronous%20development%20of%20peritoneal%5C%2Fabdominal%20HS%20and%20grade%201-2%20follicular%20lymphoma%20%28FL%29.%20Cytogenetic%20analysis%20and%20targeted%20next-generation%20sequencing%20of%20both%20FL%20and%20HS%20tumors%20identified%20common%20genomic%20alterations%20such%20as%20IGH-BCL2%20rearrangement%2C%20CREBBP%20and%20KMT2D%2C%20and%20aberrations%20of%20chromosomes%209q%20and%2019q.%20However%2C%20only%20the%20HS%20tumor%20had%20a%20KRAS%20mutation%20while%20the%20lymph%20node%20involved%20by%20FL%20harbored%20a%20TNFAIP3%20mutation%20and%20both%20tumors%20also%20showed%20distinct%20chromosomal%20alterations.%20This%20report%20strengthens%20the%20hypothesis%20of%20a%20common%20lymphoid%20progenitor%20which%20accumulates%20genetic%20alterations%20leading%20to%20two%20different%20hematologic%20malignant%20diseases%20with%20significantly%20distinct%20prognoses.%22%2C%22date%22%3A%22Dec%2005%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00428-019-02691-w%22%2C%22ISSN%22%3A%221432-2307%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A49Z%22%7D%7D%2C%7B%22key%22%3A%222HQBJAH4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sroussi%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSroussi%2C%20Marine%2C%20Reza%20Elaidi%2C%20Aude%20Fl%26%23xE9%3Bchon%2C%20Marianne%20Lorcet%2C%20Delphine%20Borchiellini%2C%20Magalie%20P.%20Tardy%2C%20Gwenaelle%20Gravis%2C%20et%20al.%20%26%23x201C%3BNeuroendocrine%20Carcinoma%20of%20the%20Urinary%20Bladder%3A%20A%20Large%2C%20Retrospective%20Study%20From%20the%20French%20Genito-Urinary%20Tumor%20Group.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Genitourinary%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20December%205%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.clgc.2019.11.014%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.clgc.2019.11.014%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neuroendocrine%20Carcinoma%20of%20the%20Urinary%20Bladder%3A%20A%20Large%2C%20Retrospective%20Study%20From%20the%20French%20Genito-Urinary%20Tumor%20Group%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Sroussi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reza%22%2C%22lastName%22%3A%22Elaidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Fl%5Cu00e9chon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marianne%22%2C%22lastName%22%3A%22Lorcet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Borchiellini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magalie%20P.%22%2C%22lastName%22%3A%22Tardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenaelle%22%2C%22lastName%22%3A%22Gravis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Gu%5Cu00e9rin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Laguerre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Estrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9mi%22%2C%22lastName%22%3A%22Delva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Phillipe%22%2C%22lastName%22%3A%22Barth%5Cu00e9l%5Cu00e9my%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohann%22%2C%22lastName%22%3A%22Loriot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pernelle%22%2C%22lastName%22%3A%22Lavaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Lebret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Neuzillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Houede%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Pouessel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Mussat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Gross-Goupil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Culine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Gauthier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Gobert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgan%22%2C%22lastName%22%3A%22Roupret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Huillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Tartas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cam%5Cu00e9lia%22%2C%22lastName%22%3A%22Radulescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Allory%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Oudard%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Neuroendocrine%20carcinoma%20of%20the%20urinary%20bladder%20%28NCUB%29%20is%20rare%2C%20accounting%20for%5Cu00a0%26lt%3B%201%25%20of%20bladder%20cancer%20cases%2C%20with%20scarce%20reported%20data%20available.%5CnMATERIALS%20AND%20METHODS%3A%20We%20retrospectively%20reviewed%20the%20data%20from%20patients%20with%20NCUB%20treated%20at%20French%20institutions.%20The%20objectives%20were%20to%20describe%20the%20patient%20characteristics%2C%20treatments%20received%2C%20and%20outcomes%20%28ie%2C%20disease-free%20survival%20%5BDFS%5D%2C%20progression-free%20survival%2C%20overall%20survival%20%5BOS%5D%29%20and%20investigate%20the%20prognostic%20factors.%5CnRESULTS%3A%20From%201997%20to%202017%2C%20we%20included%20236%20patients%2C%20173%20with%20early-stage%20NCUB%20and%2063%20with%20advanced-stage%20NCUB.%20For%20those%20with%20early-stage%20disease%2C%20the%20median%20DFS%20was%20better%20for%20the%20patients%20who%20had%20received%20cisplatin-based%20chemotherapy%20compared%20with%20carboplatin%20%28hazard%20ratio%20%5BHR%5D%2C%201.95%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%201.1-3.46%29%2C%20with%20no%20difference%20found%20between%20the%20neoadjuvant%20and%20adjuvant%20settings%20%28HR%2C%201.1%3B%2095%25%20CI%2C%200.61-1.97%29.%20The%20median%20OS%20was%2036%20months%20%2895%25%20CI%2C%2029-43%20months%29%20for%20stage%20I%20and%20II%2C%2026%20months%20%2895%25%20CI%2C%2018%20months%20to%20not%20reached%29%20for%20stage%20IIIA%2C%2016%20months%20%2895%25%20CI%2C%2012-21%20months%29%20for%20stage%20IIIB.%20The%20HR%20for%20stage%20IIIB%20compared%20with%20stage%20I%5C%2FII%20was%202.6%20%2895%25%20CI%2C%201.5-4.4%29.%20The%20DFS%20at%206%20months%20was%20associated%20with%20OS%20%28HR%2C%207.8%3B%2095%25%20CI%2C%204.1-15.0%29.%20For%20patients%20with%20metastases%20at%20diagnosis%20who%20had%20received%20chemotherapy%2C%20the%20median%20progression-free%20survival%20was%209%20months%20%2895%25%20CI%2C%208-11%29%20for%20first-line%20cisplatin%20and%206%20months%20%2895%25%20CI%2C%204-13%20months%29%20for%20carboplatin%3B%20the%20median%20OS%20was%2013%20months%20%2895%25%20CI%2C%209-15%20months%29.%20A%20high-risk%20Bajorin%20score%20%28HR%2C%2011.5%3B%2095%25%20CI%2C%201.2-112.6%29%20and%20the%20use%20of%20carboplatin%20%28HR%2C%202.26%3B%2095%25%20CI%2C%201.03-4.96%29%20were%20associated%20with%20worse%20outcomes.%5CnCONCLUSIONS%3A%20In%20early-stage%20disease%2C%20a%20shorter%20DFS%20was%20associated%20with%20worse%20OS%2C%20and%20the%20use%20of%20cisplatin%20was%20associated%20with%20better%20OS.%20For%20the%20patients%20with%20metastases%20at%20diagnosis%2C%20a%20high-risk%20Bajorin%20score%20and%20the%20use%20of%20carboplatin%20were%20associated%20with%20worse%20outcomes.%22%2C%22date%22%3A%22Dec%2005%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.clgc.2019.11.014%22%2C%22ISSN%22%3A%221938-0682%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A52Z%22%7D%7D%2C%7B%22key%22%3A%228R92KYIB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lambo%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLambo%2C%20Sander%2C%20Susanne%20N.%20Gr%26%23xF6%3Bbner%2C%20Tobias%20Rausch%2C%20Sebastian%20M.%20Waszak%2C%20Christin%20Schmidt%2C%20Aparna%20Gorthi%2C%20July%20Carolina%20Romero%2C%20et%20al.%20%26%23x201C%3BThe%20Molecular%20Landscape%20of%20ETMR%20at%20Diagnosis%20and%20Relapse.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNature%26lt%3B%5C%2Fi%26gt%3B%2C%20December%204%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41586-019-1815-x%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41586-019-1815-x%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20molecular%20landscape%20of%20ETMR%20at%20diagnosis%20and%20relapse%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sander%22%2C%22lastName%22%3A%22Lambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susanne%20N.%22%2C%22lastName%22%3A%22Gr%5Cu00f6bner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Rausch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%20M.%22%2C%22lastName%22%3A%22Waszak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christin%22%2C%22lastName%22%3A%22Schmidt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aparna%22%2C%22lastName%22%3A%22Gorthi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22July%20Carolina%22%2C%22lastName%22%3A%22Romero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monika%22%2C%22lastName%22%3A%22Mauermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%22%2C%22lastName%22%3A%22Brabetz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonja%22%2C%22lastName%22%3A%22Krausert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivo%22%2C%22lastName%22%3A%22Buchhalter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Koster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danny%20A.%22%2C%22lastName%22%3A%22Zwijnenburg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Sill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens-Martin%22%2C%22lastName%22%3A%22H%5Cu00fcbner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norman%22%2C%22lastName%22%3A%22Mack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Schwalm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Ryzhova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Volker%22%2C%22lastName%22%3A%22Hovestadt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Papillon-Cavanagh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20A.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Landgraf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Ho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Till%22%2C%22lastName%22%3A%22Milde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olaf%22%2C%22lastName%22%3A%22Witt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonas%22%2C%22lastName%22%3A%22Ecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%22%2C%22lastName%22%3A%22Sahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Sumerauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Ellison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brent%20A.%22%2C%22lastName%22%3A%22Orr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Darabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Haberler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pieter%22%2C%22lastName%22%3A%22Wesseling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%22%2C%22lastName%22%3A%22Schittenhelm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Remke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20D.%22%2C%22lastName%22%3A%22Taylor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20J.%22%2C%22lastName%22%3A%22Gil-da-Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22%5Cu0141astowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wies%5Cu0142awa%22%2C%22lastName%22%3A%22Grajkowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Hasselblatt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Hauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Torsten%22%2C%22lastName%22%3A%22Pietsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Bourdeaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Masliah-Planchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Rigau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanda%22%2C%22lastName%22%3A%22Alexandrescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Wolf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiao-Nan%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ulrich%22%2C%22lastName%22%3A%22Sch%5Cu00fcller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matija%22%2C%22lastName%22%3A%22Snuderl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%20A.%22%2C%22lastName%22%3A%22Karajannis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felice%22%2C%22lastName%22%3A%22Giangaspero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nada%22%2C%22lastName%22%3A%22Jabado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22von%20Deimling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20T.%20W.%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20O.%22%2C%22lastName%22%3A%22Korbel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katja%22%2C%22lastName%22%3A%22von%20Hoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Lichter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annie%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%20J.%20R.%22%2C%22lastName%22%3A%22Bishop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20M.%22%2C%22lastName%22%3A%22Pfister%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrey%22%2C%22lastName%22%3A%22Korshunov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Kool%22%7D%5D%2C%22abstractNote%22%3A%22Embryonal%20tumours%20with%20multilayered%20rosettes%20%28ETMRs%29%20are%20aggressive%20paediatric%20embryonal%20brain%20tumours%20with%20a%20universally%20poor%20prognosis1.%20Here%20we%20collected%20193%20primary%20ETMRs%20and%2023%20matched%20relapse%20samples%20to%20investigate%20the%20genomic%20landscape%20of%20this%20distinct%20tumour%20type.%20We%20found%20that%20patients%20with%20tumours%20in%20which%20the%20proposed%20driver%20C19MC2-4%20was%20not%20amplified%20frequently%20had%20germline%20mutations%20in%20DICER1%20or%20other%20microRNA-related%20aberrations%20such%20as%20somatic%20amplification%20of%20miR-17-92%20%28also%20known%20as%20MIR17HG%29.%20Whole-genome%20sequencing%20revealed%20that%20tumours%20had%20an%20overall%20low%20recurrence%20of%20single-nucleotide%20variants%20%28SNVs%29%2C%20but%20showed%20prevalent%20genomic%20instability%20caused%20by%20widespread%20occurrence%20of%20R-loop%20structures.%20We%20show%20that%20R-loop-associated%20chromosomal%20instability%20can%20be%20induced%20by%20the%20loss%20of%20DICER1%20function.%20Comparison%20of%20primary%20tumours%20and%20matched%20relapse%20samples%20showed%20a%20strong%20conservation%20of%20structural%20variants%2C%20but%20low%20conservation%20of%20SNVs.%20Moreover%2C%20many%20newly%20acquired%20SNVs%20are%20associated%20with%20a%20mutational%20signature%20related%20to%20cisplatin%20treatment.%20Finally%2C%20we%20show%20that%20targeting%20R-loops%20with%20topoisomerase%20and%20PARP%20inhibitors%20might%20be%20an%20effective%20treatment%20strategy%20for%20this%20deadly%20disease.%22%2C%22date%22%3A%22Dec%2004%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41586-019-1815-x%22%2C%22ISSN%22%3A%221476-4687%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A49Z%22%7D%7D%2C%7B%22key%22%3A%229U58S346%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Compaci%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCompaci%2C%20Gis%26%23xE8%3Ble%2C%20C%26%23xE9%3Bcile%20Conte%2C%20Lucie%20Oberic%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Guy%20Laurent%2C%20and%20Fabien%20Despas.%20%26%23x201C%3BSustained%20Degradation%20of%20Quality%20of%20Life%20in%20a%20Subgroup%20of%20Lymphoma%20Survivors%3A%20A%20Two-Year%20Prospective%20Survey.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2019%2C%20no.%201%20%28December%203%2C%202019%29%3A%201178.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-6337-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-6337-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sustained%20degradation%20of%20quality%20of%20life%20in%20a%20subgroup%20of%20lymphoma%20survivors%3A%20a%20two-year%20prospective%20survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gis%5Cu00e8le%22%2C%22lastName%22%3A%22Compaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Conte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Despas%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Previous%20studies%20have%20suggested%20that%20lymphoma%20survivors%20commonly%20display%20altered%20Health-Related%20Quality%20of%20Life%20%28HRQoL%29.%20Because%20these%20were%20predominantly%20cross-sectional%20studies%2C%20the%20dynamic%20of%20events%20as%20well%20as%20the%20factors%20which%20influence%20HRQoL%20remain%20to%20be%20determined.%5CnMETHODS%3A%20We%20conducted%20a%20prospective%20study%20on%20a%20cohort%20of%20204%20Hodgkin%20and%20non-Hodgkin%20lymphoma%20survivors%20who%20remained%20disease-free%202%20years%20after%20undergoing%20chemotherapy%20%28referred%20to%20the%20M0-M12-M24%20periods%29.%5CnRESULTS%3A%20We%20found%20that%20although%20Physical%20and%20Mental%20Component%20Scores%20%28PCS%20and%20MCS%29%20of%20HRQoL%20significantly%20improved%20from%20M0%20to%20M24%20in%20the%20vast%20majority%20of%20patients%20%28favorable%20group%29%2C%20approximately%2020%25%20of%20patients%20displayed%20severe%20alterations%20in%20HRQoL%20%28global%20SF-36%20scores%20%26lt%3B%5Cu200950%29%20extending%20over%20the%202-year%20period%20%28unfavorable%20group%29.%20Low%20M24%20PCSs%20were%20associated%20with%20Post-Traumatic%20Stress%20Disorder%20%28PTSD%29%2C%20depression%2C%20cardiovascular%20events%20and%20neuropathy.%20In%20contrast%20social%20determinants%2C%20comorbidity%20and%20infections%2C%20as%20well%20as%20several%20other%20parameters%20related%20to%20the%20disease%20or%20to%20the%20treatment%20itself%20were%20not%20associated%20with%20low%20M24%20PCSs.%20Low%20M24%20MCSs%20were%20associated%20with%20a%20low%20educational%20level%2C%20aggressive%20histology%2C%20infections%2C%20cardiovascular%20events%20and%20PTSS.%20However%2C%20the%20most%20predictive%20risk%20factor%20for%20low%20SF-36%20scores%20at%20M24%20was%20a%20low%20SF-36%20score%20at%20M12.%20The%20unfavorable%20group%20also%20displayed%20a%20low%20incidence%20of%20return%20to%20work.%5CnCONCLUSIONS%3A%20Although%20the%20HRQoL%20of%20lymphoma%20survivors%20generally%20improved%20over%20time%2C%20persistent%20and%20severe%20HRQoL%20alterations%20still%20affected%20approximately%20one%20fifth%20of%20patients%2C%20resulting%20in%20important%20social%20consequences.%20This%20specific%20group%2C%20which%20presents%20with%20identifiable%20risk%20factors%2C%20may%20benefit%20from%20early%2C%20targeted%20psycho-social%20support.%22%2C%22date%22%3A%22Dec%2003%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-019-6337-2%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22E4Q6JJSS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dubucs%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDubucs%2C%20Charlotte%2C%20C%26%23xE9%3Bline%20Basset%2C%20Dominique%20D%26%23x2019%3BAure%2C%20Monique%20Courtade-Sa%26%23xEF%3Bdi%2C%20and%20Sol%26%23xE8%3Bne%20M.%20Evrard.%20%26%23x201C%3BA%204-Year%20Retrospective%20Analysis%20of%20Salivary%20Gland%20Cytopathology%20Using%20the%20Milan%20System%20for%20Reporting%20Salivary%20Gland%20Cytology%20and%20Ancillary%20Studies.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2011%2C%20no.%2012%20%28December%201%2C%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11121912%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11121912%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%204-Year%20Retrospective%20Analysis%20of%20Salivary%20Gland%20Cytopathology%20Using%20the%20Milan%20System%20for%20Reporting%20Salivary%20Gland%20Cytology%20and%20Ancillary%20Studies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Dubucs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Basset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22D%27Aure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Courtade-Sa%5Cu00efdi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%20M.%22%2C%22lastName%22%3A%22Evrard%22%7D%5D%2C%22abstractNote%22%3A%22The%20cytopathology%20of%20salivary%20glands%20presents%20major%20challenges%20due%20to%20the%20heterogeneity%20of%20benign%20and%20malignant%20neoplasms%2C%20which%20is%20reflected%20in%20the%20large%20range%20of%20WHO%202017%20Classifications.%20Fine%20needle%20aspiration%20%28FNA%29%20of%20salivary%20gland%20tumours%20is%20still%20the%20favoured%20initial%20approach%20as%20it%20results%20in%20good%20sensitivity%20and%20specificity.%20The%20Milan%20System%20for%20Reporting%20Salivary%20Gland%20Cytopathology%20%28MSRSGC%29%20was%20published%20in%202018%20and%20comprises%20seven%20categories.%20We%20report%20results%20from%20a%204-year%20retrospective%20analysis%20of%20328%20salivary%20gland%20FNAs%20which%20were%20reviewed%20and%20classified%20according%20to%20the%20MSRSGC.%20We%20assess%20the%20risk%20of%20neoplasm%2C%20the%20risk%20of%20malignancy%20and%20the%20contribution%20of%20ancillary%20studies%20to%20the%20diagnosis.%20Benign%20neoplasms%20were%20the%20most%20frequent%20diagnosis%20%2844.2%25%29.%20Malignant%20and%20suspicious%20for%20malignancy%20were%20identified%20in%2011.3%25%20and%204.9%25%20of%20diagnosed%20cases%2C%20respectively.%20Histopathological%20analysis%20after%20surgery%20was%20available%20for%20216%20%2865.8%25%29%20of%20the%20cases.%20All%20malignant%20cases%20were%20confirmed%20post-surgery%2C%20and%2068.8%25%20of%20suspicious%20for%20malignancy%20were%20confirmed%20as%20malignant%20tumours.%20Immunocytochemistry%20was%20informative%20in%2072.3%25%20of%20cases.%20Immunocytochemistry%20and%20FISH%20provided%20the%20definitive%20diagnosis%20in%2023.7%25%20and%2033%25%20of%20cases%2C%20respectively.%20In%20conclusion%2C%20the%20MSRSGC%20is%20more%20effective%20when%20specific%20features%20of%20neoplasms%20can%20be%20identified.%20Ancillary%20studies%20help%20to%20further%20characterise%20salivary%20gland%20tumours%20and%20thereby%20increase%20the%20accuracy%20of%20MSRSGC.%22%2C%22date%22%3A%22Dec%2001%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers11121912%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22596YGAS4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Voron%20et%20al.%22%2C%22parsedDate%22%3A%222019-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVoron%2C%20Thibault%2C%20Caroline%20Gronnier%2C%20Arnaud%20Pasquer%2C%20Jeremie%20Thereaux%2C%20Johan%20Gagniere%2C%20Gil%20Lebreton%2C%20Bernard%20Meunier%2C%20et%20al.%20%26%23x201C%3BAdenocarcinoma%20of%20the%20Oesophagogastric%20Junction%20Siewert%20II%3A%20An%20Oesophageal%20Cancer%20Better%20Cured%20with%20Total%20Gastrectomy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Surgical%20Oncology%3A%20The%20Journal%20of%20the%20European%20Society%20of%20Surgical%20Oncology%20and%20the%20British%20Association%20of%20Surgical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2045%2C%20no.%2012%20%28December%202019%29%3A%202473%26%23x2013%3B81.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2019.07.022%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2019.07.022%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Adenocarcinoma%20of%20the%20oesophagogastric%20junction%20Siewert%20II%3A%20An%20oesophageal%20cancer%20better%20cured%20with%20total%20gastrectomy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Voron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Gronnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pasquer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremie%22%2C%22lastName%22%3A%22Thereaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Gagniere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gil%22%2C%22lastName%22%3A%22Lebreton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Meunier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Collet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Piessen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Paye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22FREGAT%20working%20group%20-%20FRENCH%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Type%20II%20AEG%20is%20now%20considered%20as%20oesophageal%20cancer%20in%20the%20seventh%20and%20eighth%20edition%20of%20TNM%20classification%20but%20optimal%20surgical%20approach%20for%20these%20tumors%20remains%20debated.%20The%20objective%20of%20the%20study%20is%20to%20assess%20and%20compare%20surgical%20and%20oncological%20outcomes%20of%20two%20surgical%20approaches%3A%20superior%20polar%20oesogastrectomy%20%28SPO%29%20or%20total%20gastrectomy%20%28TG%29%20in%20patients%20with%20type%20II%20adenocarcinoma%20of%20the%20oesophagogastric%20junction%20%28AEG%29.%5CnMATERIAL%20AND%20METHODS%3A%20183%20patients%20with%20type%20II%20AEG%20treated%20from%201997%20to%202010%20in%2021%20French%20centers%20by%20SPO%20or%20TG%20were%20included%20in%20a%20multicenter%20retrospective%20study.%20The%20surgical%20and%20oncological%20outcomes%20were%20compared%20between%20these%20two%20surgical%20approaches.%5CnRESULTS%3A%20A%20TG%20was%20performed%20in%2064%20%2835%25%29%20patients%20whereas%20119%20%2865%25%29%20patients%20were%20treated%20by%20SPO%20with%20transthoracic%20approach%20in%20100%20of%20them%20%2883.2%25%29%20and%20transhiatal%20approach%20with%20cervicotomy%20in%2019%20%2816.8%25%29.%20Surgical%20outcomes%20were%20comparable%20between%20the%20two%20approaches%20with%20a%20postoperative%20mortality%20rate%20of%204.9%25%20and%20a%20severe%20operative%20morbidity%20rate%20within%2030%20days%20of%2015.3%25.%20Median%20survival%20in%20patients%20operated%20on%20by%20TG%20was%20of%2046%20months%20compared%20to%2027%20months%20in%20patients%20treated%20by%20SPO%20%28p%5Cu202f%3D%5Cu202f0.118%29.%20At%20multivariate%20analysis%2C%20TG%20appears%20to%20be%20an%20independent%20good%20prognostic%20factor%20compared%20to%20SPO%20%28HR%5Cu202f%3D%5Cu202f1.847%3B%20p%5Cu202f%3D%5Cu202f0.008%29.%20However%2C%20TG%20was%20also%20associated%20with%20a%20higher%20rate%20of%20incomplete%20resection%2C%20%2812.5%25%20vs%205.9%25%3B%20p%5Cu202f%3D%5Cu202f0.120%29.%5CnCONCLUSION%3A%20When%20TG%20allows%20obtaining%20tumor-free%20resection%20margins%2C%20this%20approach%20should%20be%20preferred%20to%20SPO.%22%2C%22date%22%3A%22Dec%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejso.2019.07.022%22%2C%22ISSN%22%3A%221532-2157%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22ZCJHIFVC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lesur%20et%20al.%22%2C%22parsedDate%22%3A%222019-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLesur%2C%20Anne%2C%20Florence%20Dalenc%2C%20and%20Marie%20Beguignot.%20%26%23x201C%3B%5BAdjuvant%20endocrine%20therapy%20in%20premenopausal%20breast%20cancer%3A%20a%20initial%20dedicated%20counseling%3A%20can%20it%20be%20useful%20for%20better%20adherence%3F%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBulletin%20Du%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20106%2C%20no.%2012S1%20%28December%202019%29%3A%20S28%26%23x2013%3B36.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0007-4551%2820%2930045-X%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0007-4551%2820%2930045-X%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BAdjuvant%20endocrine%20therapy%20in%20premenopausal%20breast%20cancer%3A%20a%20initial%20dedicated%20counseling%3A%20can%20it%20be%20useful%20for%20better%20adherence%3F%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Lesur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dalenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Beguignot%22%7D%5D%2C%22abstractNote%22%3A%22Adjuvant%20endocrine%20therapy%20is%20highly%20effective%20and%20appropriate%20for%20all%20breast%20cancer%20patients%20with%20hormone%20receptor%20positive%20tumors%2C%20pre%20and%20post%20menopausal%20women.%20It%26%23039%3Bs%20an%20oral%20daily%20pill%20for%20many%20years%2C%20after%20primary%20treatment.%20Although%20this%20medication%20dramatically%20reduces%20reccurrence%20rates%20and%20risk%20of%20death%2C%20many%20breast%20cancer%20survivors%20either%20fail%20to%20take%20pills%20with%20prescribed%20frequency%20%28adherence%29%20or%20discontinue%20therapy%20%28persistence%29%20or%20even%20never%20begin%20to%20take%20it.%20It%26%23039%3Bs%20difficult%20to%20know%20exactly%20the%20prevalence%20of%20adherence%20and%20persistence%20but%20women%20age%20younger%20than%2040%20years%20had%20the%20highest%20risk%20of%20discontinuation.%20Medical%20literature%20of%20the%20last%2015%20years%20in%20this%20area%20has%20been%20carefully%20reviewed%20considering%20initiation%20treatment%20background%2C%20specificity%20of%20premenopausal%20young%20women%20population%2C%20healthcare%20provider%20and%20patient%20communication%20and%20respective%20views.%20It%26%23039%3Bs%20highlighted%20that%20dedicated%20care%2C%20at%20first%20and%20after%20in%20follow%20up%2C%20is%20an%20essential%20part%20for%20better%20adherence.%20Guidelines%20processing%20are%20more%20and%20more%20complicated%2C%20expert%20medical%20assesment%20is%20required%2C%20shared%20decision%20must%20be%20provide.%20Patients%20need%20enhanced%20knowledge%20about%20mode%20of%20action%2C%20benefits%20but%20also%20potential%20side%20effects%2C%20and%20optimized%20patient%20provider%20relationship%20for%20empathy%20and%20better%20comprehension.%20Providers%20must%20believe%20in%20treatment%20relevance%20and%20convey%20their%20convictions.%22%2C%22date%22%3A%22Dec%202019%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2FS0007-4551%2820%2930045-X%22%2C%22ISSN%22%3A%221769-6917%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22G3QHW7RV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vergez%20et%20al.%22%2C%22parsedDate%22%3A%222019-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVergez%2C%20Fran%26%23xE7%3Bois%2C%20Laetitia%20Largeaud%2C%20Lucie%20Oberic%2C%20and%20Jean-Baptiste%20Rieu.%20%26%23x201C%3BDo%20Not%20Jump%20to%20Hasty%20Conclusions%3A%20All%20Gamma%20Delta%20T-Cells%20Neoplasms%20Are%20Not%20Aggressive%21%26%23x201D%3B%20%26lt%3Bi%26gt%3BBlood%20Research%26lt%3B%5C%2Fi%26gt%3B%2054%2C%20no.%204%20%28December%202019%29%3A%20243.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5045%5C%2Fbr.2019.54.4.243%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5045%5C%2Fbr.2019.54.4.243%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Do%20not%20jump%20to%20hasty%20conclusions%3A%20all%20gamma%20delta%20T-cells%20neoplasms%20are%20not%20aggressive%21%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Dec%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.5045%5C%2Fbr.2019.54.4.243%22%2C%22ISSN%22%3A%222287-979X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A55Z%22%7D%7D%2C%7B%22key%22%3A%225AYUSFWT%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guillaume%20et%20al.%22%2C%22parsedDate%22%3A%222019-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuillaume%2C%20Maeva%2C%20Valerie%20Moal%2C%20Cyrielle%20Delabaudiere%2C%20Floraine%20Zuberbuhler%2C%20Marie-Ang%26%23xE8%3Ble%20Robic%2C%20Adrien%20Lannes%2C%20Sophie%20Metivier%2C%20et%20al.%20%26%23x201C%3BDirect%20Comparison%20of%20the%20Specialised%20Blood%20Fibrosis%20Tests%20FibroMeterV2G%20and%20Enhanced%20Liver%20Fibrosis%20Score%20in%20Patients%20with%20Non-Alcoholic%20Fatty%20Liver%20Disease%20from%20Tertiary%20Care%20Centres.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAlimentary%20Pharmacology%20%26amp%3B%20Therapeutics%26lt%3B%5C%2Fi%26gt%3B%2050%2C%20no.%2011%26%23x2013%3B12%20%28December%202019%29%3A%201214%26%23x2013%3B22.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fapt.15529%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fapt.15529%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Direct%20comparison%20of%20the%20specialised%20blood%20fibrosis%20tests%20FibroMeterV2G%20and%20Enhanced%20Liver%20Fibrosis%20score%20in%20patients%20with%20non-alcoholic%20fatty%20liver%20disease%20from%20tertiary%20care%20centres%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maeva%22%2C%22lastName%22%3A%22Guillaume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerie%22%2C%22lastName%22%3A%22Moal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyrielle%22%2C%22lastName%22%3A%22Delabaudiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floraine%22%2C%22lastName%22%3A%22Zuberbuhler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Ang%5Cu00e8le%22%2C%22lastName%22%3A%22Robic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Lannes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Metivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Oberti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Gourdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Fouchard-Hubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Michalak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marie%22%2C%22lastName%22%3A%22Peron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Cales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Bureau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Boursier%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20Enhanced%20Liver%20Fibrosis%20score%20%28ELF%29%20and%20the%20FibroMeterV2G%20are%20two%20specialized%20blood%20fibrosis%20tests%20which%20include%20direct%20markers%20of%20liver%20fibrosis.%20They%20have%20been%20shown%20to%20be%20more%20accurate%20than%20the%20simple%20blood%20fibrosis%20tests%20FIB4%20and%20the%20non-alcoholic%20fatty%20liver%20disease%20%28NAFLD%29%20fibrosis%20score%20%28NFS%29.%5CnAIMS%3A%20To%20directly%20compare%20the%20accuracies%20of%20ELF%20and%20FibroMeterV2G%20for%20the%20non-invasive%20diagnosis%20of%20liver%20fibrosis%20in%20NAFLD.%5CnMETHODS%3A%20Four%20hundred%20and%20seventeen%20patients%20with%20biopsy-proven%20NAFLD%20were%20enrolled%20from%20two%20tertiary%20care%20centres.%20Four%20blood%20fibrosis%20tests%20were%20calculated%3A%20ELF%2C%20FibroMeterV2G%20%2C%20NFS%2C%20and%20FIB4.%20Advanced%20fibrosis%20F3%5C%2F4%20on%20liver%20biopsy%20%28NASH%20CRN%20scoring%29%20was%20the%20primary%20endpoint.%5CnRESULTS%3A%20Areas%20under%20the%20receiver%20operating%20characteristic%20%28AUROC%29%20curve%20for%20advanced%20fibrosis%20were%20not%20significantly%20different%20between%20the%20direct%20markers%20of%20liver%20fibrosis%20%28hyaluronate%2C%20PIIINP%2C%20TIMP-1%2C%20alpha2-macroglobulin%29%20and%20the%20simple%20blood%20fibrosis%20tests%20NFS%20and%20FIB4.%20ELF%20%280.793%5Cu00a0%5Cu00b1%5Cu00a00.022%29%20and%20FibroMeterV2G%20%280.804%5Cu00a0%5Cu00b1%5Cu00a00.021%29%20had%20significantly%20higher%20AUROC%20than%20NFS%20%280.722%5Cu00a0%5Cu00b1%5Cu00a00.025%2C%20P%5Cu00a0%26lt%3B%5Cu00a0.010%29%20and%20FIB4%20%280.739%5Cu00a0%5Cu00b1%5Cu00a00.024%2C%20P%5Cu00a0%26lt%3B%5Cu00a0.020%29.%20AUROC%20for%20advanced%20fibrosis%20and%20Obuchowski%20index%20were%20not%20significantly%20different%20between%20ELF%20and%20FibroMeterV2G%20.%20Algorithms%20using%20first%20ELF%20or%20FibroMeterV2G%20and%20then%20liver%20biopsy%20in%20case%20of%20undetermined%20diagnosis%20provided%20high%20diagnostic%20accuracy%20for%20advanced%20fibrosis%3A%2090%25%20sensitivity%2C%2090%25%20specificity%2C%2093%25%20negative%20predictive%20value%2C%2085%25%20positive%20predictive%20value%2C%20and%2090%25%20correct%20classification.%20In%20these%20algorithms%2C%20the%20rate%20of%20liver%20biopsy%20was%2045.3%25%20with%20ELF%20versus%2039.3%25%20with%20FibroMeterV2G%20%28P%5Cu00a0%3D%5Cu00a0.065%29.%5CnCONCLUSIONS%3A%20ELF%20and%20FibroMeterV2G%20have%20equal%20accuracy%20and%20perform%20better%20than%20the%20simple%20FIB4%20and%20NFS%20tests%20for%20the%20non-invasive%20diagnosis%20of%20advanced%20liver%20fibrosis%20in%20patients%20with%20NAFLD%20from%20tertiary%20care%20centres.%22%2C%22date%22%3A%22Dec%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fapt.15529%22%2C%22ISSN%22%3A%221365-2036%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22D6D8QKLR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kabor%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222019-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKabor%26%23xE9%3B%2C%20Elis%26%23xE9%3B%20G.%2C%20Charles%20Guenancia%2C%20Ines%20Vaz-Luis%2C%20Antonio%20Di%20Meglio%2C%20Barbara%20Pistilli%2C%20Charles%20Coutant%2C%20Paul%20Cottu%2C%20et%20al.%20%26%23x201C%3BAssociation%20of%20Body%20Mass%20Index%20and%20Cardiotoxicity%20Related%20to%20Anthracyclines%20and%20Trastuzumab%20in%20Early%20Breast%20Cancer%3A%20French%20CANTO%20Cohort%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BPLoS%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2016%2C%20no.%2012%20%28December%202019%29%3A%20e1002989.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1002989%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1002989%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20body%20mass%20index%20and%20cardiotoxicity%20related%20to%20anthracyclines%20and%20trastuzumab%20in%20early%20breast%20cancer%3A%20French%20CANTO%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elis%5Cu00e9%20G.%22%2C%22lastName%22%3A%22Kabor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Guenancia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Vaz-Luis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Di%20Meglio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Pistilli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Coutant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Cottu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Lesur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Petit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dalenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rouanet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Arnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Arsene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmoud%22%2C%22lastName%22%3A%22Ibrahim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanna%22%2C%22lastName%22%3A%22Wassermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Genevi%5Cu00e8ve%22%2C%22lastName%22%3A%22Boileau-Jolimoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Lemonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Andr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Arveux%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20In%20patients%20treated%20with%20cardiotoxic%20chemotherapies%2C%20the%20presence%20of%20cardiovascular%20risk%20factors%20and%20previous%20cardiac%20disease%20have%20been%20strongly%20correlated%20to%20the%20onset%20of%20cardiotoxicity.%20The%20influence%20of%20overweight%20and%20obesity%20as%20risk%20factors%20in%20the%20development%20of%20treatment-related%20cardiotoxicity%20in%20breast%20cancer%20%28BC%29%20was%20recently%20suggested.%20However%2C%20due%20to%20meta-analysis%20design%2C%20it%20was%20not%20possible%20to%20take%20into%20account%20associated%20cardiac%20risk%20factors%20or%20other%20classic%20risk%20factors%20for%20anthracycline%20%28antineoplastic%20antibiotic%29%20and%20trastuzumab%20%28monoclonal%20antibody%29%20cardiotoxicity.%5CnMETHODS%20AND%20FINDINGS%3A%20Using%20prospective%20data%20collected%20from%202012-2014%20in%20the%20French%20national%20multicenter%20prospective%20CANTO%20%28CANcer%20TOxicities%29%20study%20of%2026%20French%20cancer%20centers%2C%20we%20aimed%20to%20examine%20the%20association%20of%20body%20mass%20index%20%28BMI%29%20and%20cardiotoxicity%20%28defined%20as%20a%20reduction%20in%20left%20ventricular%20ejection%20fraction%20%5BLVEF%5D%20%26gt%3B%2010%20percentage%20points%20from%20baseline%20to%20LVEF%20%26lt%3B%2050%25%29.%20In%20total%2C%20929%20patients%20with%20stage%20I-III%20BC%20%28mean%20age%2052%20%5Cu00b1%2011%20years%2C%20mean%20BMI%2025.6%20%5Cu00b1%205.1%20kg%5C%2Fm2%2C%2042%25%20with%201%20or%20more%20cardiovascular%20risk%20factors%29%20treated%20with%20anthracycline%20%2886%25%20epirubicin%2C%207%25%20doxorubicin%29%20and%5C%2For%20trastuzumab%20%2836%25%29%2C%20with%20LVEF%20measurement%20at%20baseline%20and%20at%20least%201%20assessment%20post-chemotherapy%20were%20eligible%20in%20this%20interim%20analysis.%20We%20analyzed%20associations%20between%20BMI%20and%20cardiotoxicity%20using%20multivariate%20logistic%20regression.%20At%20baseline%2C%20nearly%2050%25%20of%20the%20study%20population%20was%20overweight%20or%20obese.%20During%20a%20mean%20follow-up%20of%2022%20%5Cu00b1%202%20months%20following%20treatment%20completion%2C%20cardiotoxicity%20occurred%20in%2029%20patients%20%283.2%25%29.%20The%20obese%20group%20was%20more%20prone%20to%20cardiotoxicity%20than%20the%20normal-weight%20group%20%289%5C%2F171%20versus%208%5C%2F466%3B%20p%20%3D%200.01%29.%20In%20multivariate%20analysis%2C%20obesity%20%28odds%20ratio%20%5BOR%5D%203.02%3B%2095%25%20CI%201.10-8.25%3B%20p%20%3D%200.03%29%20and%20administration%20of%20trastuzumab%20%28OR%2012.12%3B%2095%25%20CI%203.6-40.4%3B%20p%20%26lt%3B%200.001%29%20were%20independently%20associated%20with%20cardiotoxicity.%20Selection%20bias%20and%20relatively%20short%20follow-up%20are%20potential%20limitations%20of%20this%20national%20multicenter%20observational%20cohort.%5CnCONCLUSIONS%3A%20In%20BC%20patients%2C%20obesity%20appears%20to%20be%20associated%20with%20an%20important%20increase%20in%20risk-related%20cardiotoxicity%20%28CANTO%2C%20ClinicalTrials.gov%20registry%20ID%3A%20NCT01993498%29.%5CnTRIAL%20REGISTRATION%3A%20ClinicalTrials.gov%20NCT01993498.%22%2C%22date%22%3A%22Dec%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1002989%22%2C%22ISSN%22%3A%221549-1676%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22FLW3BLLK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Heidegger%20et%20al.%22%2C%22parsedDate%22%3A%222019-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHeidegger%2C%20Isabel%2C%20Igor%20Tsaur%2C%20Hendrik%20Borgmann%2C%20Christian%20Surcel%2C%20Alexander%20Kretschmer%2C%20Romain%20Mathieu%2C%20Pieter%20De%20Visschere%2C%20et%20al.%20%26%23x201C%3BHereditary%20Prostate%20Cancer%20-%20Primetime%20for%20Genetic%20Testing%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Treatment%20Reviews%26lt%3B%5C%2Fi%26gt%3B%2081%20%28December%202019%29%3A%20101927.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ctrv.2019.101927%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ctrv.2019.101927%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hereditary%20prostate%20cancer%20-%20Primetime%20for%20genetic%20testing%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabel%22%2C%22lastName%22%3A%22Heidegger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igor%22%2C%22lastName%22%3A%22Tsaur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hendrik%22%2C%22lastName%22%3A%22Borgmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Surcel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Kretschmer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Mathieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pieter%20De%22%2C%22lastName%22%3A%22Visschere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Massimo%22%2C%22lastName%22%3A%22Valerio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roderick%20C.%20N.%22%2C%22lastName%22%3A%22van%20den%20Bergh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Piet%22%2C%22lastName%22%3A%22Ost%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Derya%22%2C%22lastName%22%3A%22Tilki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giorgio%22%2C%22lastName%22%3A%22Gandaglia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Ploussard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22EAU-YAU%20Prostate%20Cancer%20Working%20Party%22%7D%5D%2C%22abstractNote%22%3A%22Prostate%20cancer%20%28PCa%29%20remains%20the%20most%20common%20cancer%20in%20men.%20The%20proportion%20of%20all%20PCa%20attributable%20to%20high-risk%20hereditary%20factors%20has%20been%20estimated%20to%205-15%25.%20Recent%20landmark%20discoveries%20in%20PCa%20genetics%20led%20to%20the%20identification%20of%20germline%20mutations%5C%2Falterations%20%28eg.%20BRCA1%2C%20BRCA2%2C%20ATM%20or%20HOXB13%29%2C%20single%20nucleotide%20polymorphisms%20or%20copy%20number%20variations%20associated%20with%20PCa%20incidence%20and%20progression.%20However%2C%20offering%20germline%20testing%20to%20men%20with%20an%20assumed%20hereditary%20component%20is%20currently%20controversial.%20In%20the%20present%20review%20article%2C%20we%20provide%20an%20overview%20about%20the%20epidemiology%20and%20the%20genetic%20basis%20of%20PCa%20predisposition%20and%20critically%20discuss%20the%20significance%20and%20consequence%20in%20the%20clinical%20routine.%20In%20addition%2C%20we%20give%20an%20overview%20about%20genetic%20tests%20and%20report%20latest%20findings%20from%20ongoing%20clinical%20studies.%20Lastly%2C%20we%20discuss%20the%20impact%20of%20genetic%20testing%20in%20personalized%20therapy%20in%20advanced%20stages%20of%20the%20disease.%22%2C%22date%22%3A%22Dec%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ctrv.2019.101927%22%2C%22ISSN%22%3A%221532-1967%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22GLHKI2M9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Steinmeyer%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSteinmeyer%2C%20Zara%2C%20St%26%23xE9%3Bphane%20G%26%23xE9%3Brard%2C%20Thomas%20Filleron%2C%20St%26%23xE9%3Bphanie%20Lozano%2C%20Delphine%20Brechemier%2C%20Gabor%20Abellan%20Van%20Kan%2C%20Loic%20Mourey%2C%20et%20al.%20%26%23x201C%3BLow%20Lean%20Mass%20and%20Chemotherapy%20Toxicity%20Risk%20in%20the%20Elderly%3A%20The%20Fraction%20Study%20Protocol.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2019%2C%20no.%201%20%28November%2027%2C%202019%29%3A%201153.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-6377-7%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-6377-7%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Low%20lean%20mass%20and%20chemotherapy%20toxicity%20risk%20in%20the%20elderly%3A%20the%20Fraction%20study%20protocol%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zara%22%2C%22lastName%22%3A%22Steinmeyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22G%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Lozano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Brechemier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabor%22%2C%22lastName%22%3A%22Abellan%20Van%20Kan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Mourey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Cristol-Dalstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22De%20Decker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Rolland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Balardy%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Half%20of%20cancer%20cases%20occur%20in%20patients%20aged%2070%20and%20above.%20Majority%20of%20older%20patients%20are%20eligible%20for%20chemotherapy%20but%20evidence%20for%20treating%20this%20population%20is%20sparse%20and%20severe%20toxicities%20affect%20more%20than%20half%20of%20them.%20Determining%20prognostic%20biomarkers%20able%20to%20predict%20poor%20chemotherapy%20tolerance%20remains%20one%20of%20the%20major%20issues%20in%20geriatric%20oncology.%20Ageing%20is%20associated%20with%20body%20composition%20changes%20%28increase%20of%20fat%20mass%20and%20loss%20of%20lean%20mass%29%20independently%20of%20weight-loss.%20Previous%20studies%20suggest%20that%20body%20composition%20parameters%20%28particularly%20muscle%20mass%29%20may%20predict%20poor%20chemotherapy%20tolerance.%20However%2C%20studies%20specifically%20including%20older%20adults%20on%20this%20subject%20remain%20sparse%20and%20the%20majority%20of%20them%20study%20body%20composition%20based%20on%20computed%20tomography%20%28CT%29%20scanner%20%28axial%20L3%20section%29%20muscle%20mass%20estimation.%20This%20method%20is%20to%20date%20not%20validated%20in%20elderly%20cancer%20patients.%5CnMETHODS%3A%20This%20trial%20%28Fraction%29%20will%20evaluate%20the%20discriminative%20ability%20of%20appendicular%20lean%20mass%20measured%20by%20dual-energy%20X-ray%20absorptiometry%20%28DXA%29%20to%20predict%20severe%20toxicity%20incidence%20in%20older%20cancer-patients%20treated%20with%20first-line%20chemotherapy.%20DXA%20is%20considered%20the%20gold%20standard%20in%20body%20composition%20assessment%20in%20older%20adults.%20Patient%26%23039%3Bs%20aged%20%5Cu226570%20diagnosed%20with%20solid%20neoplasms%20or%20lymphomas%20at%20a%20locally%20advanced%20or%20metastatic%20stage%20treated%20for%20first-line%20chemotherapy%20were%20recruited.%20Patients%20completed%20a%20pre-chemotherapy%20assessment%20that%20recorded%20socio-demographics%2C%20tumor%5C%2Ftreatment%20variables%2C%20laboratory%20test%20results%2C%20geriatric%20assessment%20variables%20%28function%2C%20comorbidity%2C%20cognition%2C%20social%20support%20and%20nutritional%20status%29%2C%20oncological%20risk%20scores%20and%20body%20composition%20with%20DXA.%20Appendicular%20lean%20mass%20was%20standardized%20using%20evidence%20based%20international%20criteria.%20Participants%20underwent%20short%20follow-up%20geriatric%20assessments%20within%20the%20first%203%5Cu2009months%2C%206%5Cu2009months%20and%20a%20year%20after%20inclusion.%20Grade%203%20to%205%20chemotherapy-related%20toxicities%2C%20as%20defined%20by%20the%20National%20Cancer%20Institute%20Common%20Terminology%20Criteria%20for%20Adverse%20Events%20%28NCI%20CTCAE%29%20were%20assessed%20at%20each%20chemotherapy%20cycle.%5CnDISCUSSION%3A%20The%20finding%20that%20body%20composition%20is%20associated%20with%20poor%20tolerance%20of%20chemotherapy%20could%20lead%20to%20consider%20these%20parameters%20as%20well%20as%20improve%20current%20decision-making%20algorithms%20when%20treating%20older%20adults.%5CnTRIAL%20REGISTRATION%3A%20ClinicalTrials.gov%20Identifier%3A%20NCT02806154%20registered%20on%20October%202016.%22%2C%22date%22%3A%22Nov%2027%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-019-6377-7%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22FY8A344V%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Flot%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-26%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFlot%2C%20Claire%2C%20Isabelle%20Oliver%2C%20Philippe%20Caron%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%20Savagner%2C%20Maith%26%23xE9%3B%20Tauber%2C%20S%26%23xE9%3Bgol%26%23xE8%3Bne%20Claeyssens%2C%20and%20Thomas%20Edouard.%20%26%23x201C%3BAcquired%20von%20Willebrand%26%23x2019%3Bs%20Syndrome%20Caused%20by%20Primary%20Hypothyroidism%20in%20a%205-Year-Old%20Girl.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Pediatric%20Endocrinology%20%26amp%3B%20Metabolism%3A%20JPEM%26lt%3B%5C%2Fi%26gt%3B%2032%2C%20no.%2011%20%28November%2026%2C%202019%29%3A%201295%26%23x2013%3B98.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1515%5C%2Fjpem-2019-0082%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1515%5C%2Fjpem-2019-0082%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acquired%20von%20Willebrand%27s%20syndrome%20caused%20by%20primary%20hypothyroidism%20in%20a%205-year-old%20girl%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Flot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Oliver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Caron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Savagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maith%5Cu00e9%22%2C%22lastName%22%3A%22Tauber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9gol%5Cu00e8ne%22%2C%22lastName%22%3A%22Claeyssens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Edouard%22%7D%5D%2C%22abstractNote%22%3A%22Background%20Acquired%20von%20Willebrand%26%23039%3Bs%20syndrome%20%28aVWS%29%20associated%20with%20hypothyroidism%20is%20rare%20in%20children%20and%20more%20often%20diagnosed%20during%20the%20peripubertal%20period%20in%20the%20context%20of%20Hashimoto%26%23039%3Bs%20thyroiditis.%20Case%20presentation%20A%205-year-old%20girl%20was%20referred%20to%20the%20paediatric%20haematology%20unit%20for%20rectal%20bleeding%2C%20anaemia%20and%20prolonged%20activated%20partial%20thromboplastin%20time%20%28aPTT%29.%20Her%20developmental%20and%20learning%20skills%20were%20normal.%20The%20physical%20examination%20revealed%20severe%20short%20stature%20%28height%20SDS%3A%20-3.6%29%20with%20overweight%20%28body%20mass%20index%20SDS%3A%201.8%29%20and%20clinical%20sign%20of%20hypothyroidism.%20Laboratory%20investigation%20revealed%20aVWS%20type%201%20associated%20with%20severe%20primary%20hypothyroidism.%20Anti-thyroid%20antibodies%20were%20negative%20and%20thyroid%20ultrasound%20found%20thyroid%20hypoplasia%20in%20favour%20of%20congenital%20hypothyroidism.%20Restoration%20of%20euthyroidism%20was%20associated%20with%20increased%20growth%20velocity%20and%20normalisation%20of%20coagulation%20parameters.%20Conclusion%20This%20report%20highlights%20the%20importance%20of%20excluding%20an%20underlying%20pathology%20%28including%20hypothyroidism%29%20in%20children%20with%20suspected%20VWS%2C%20even%20in%20young%20age.%22%2C%22date%22%3A%22Nov%2026%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1515%5C%2Fjpem-2019-0082%22%2C%22ISSN%22%3A%222191-0251%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-10-11T11%3A34%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22ENTR7QHX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vasseur%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVasseur%2C%20Antoine%2C%20Luc%20Cabel%2C%20Olivier%20Tredan%2C%20Marion%20Chevrier%2C%20Coraline%20Dubot%2C%20V%26%23xE9%3Bronique%20Lorgis%2C%20William%20Jacot%2C%20et%20al.%20%26%23x201C%3BPrognostic%20Value%20of%20CEC%20Count%20in%20HER2-Negative%20Metastatic%20Breast%20Cancer%20Patients%20Treated%20with%20Bevacizumab%20and%20Chemotherapy%3A%20A%20Prospective%20Validation%20Study%20%28UCBG%20COMET%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAngiogenesis%26lt%3B%5C%2Fi%26gt%3B%2C%20November%2026%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10456-019-09697-7%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10456-019-09697-7%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prognostic%20value%20of%20CEC%20count%20in%20HER2-negative%20metastatic%20breast%20cancer%20patients%20treated%20with%20bevacizumab%20and%20chemotherapy%3A%20a%20prospective%20validation%20study%20%28UCBG%20COMET%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Vasseur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Cabel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Tredan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Chevrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coraline%22%2C%22lastName%22%3A%22Dubot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Lorgis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Jacot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Goncalves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debled%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Levy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Ferrero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Jouannaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Luporsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Ange%22%2C%22lastName%22%3A%22Mouret-Reynier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dalenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Lemonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexia%22%2C%22lastName%22%3A%22Savignoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Tanguy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois-Clement%22%2C%22lastName%22%3A%22Bidard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Pierga%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Proof%20of%20concept%20studies%20has%20reported%20that%20circulating%20endothelial%20cell%20%28CEC%29%20count%20may%20be%20associated%20with%20the%20outcome%20of%20HER2-negative%20metastatic%20breast%20cancer%20%28mBC%29%20patients%20treated%20by%20chemotherapy%20and%20the%20anti-VEGF%20antibody%20bevacizumab.%20We%20report%20the%20results%20obtained%20in%20an%20independent%20prospective%20validation%20cohort%20%28COMET%20study%2C%20NCT01745757%29.%5CnMETHODS%3A%20The%20main%20baseline%20criteria%20were%20HER2-negative%20mBC%2C%20performance%20status%200-2%20and%20no%20prior%20chemotherapy%20for%20metastatic%20disease.%20CECs%20were%20detected%20by%20CellSearch%5Cu00ae%20from%204%5Cu00a0ml%20of%20blood%20at%20baseline%20and%20after%204%5Cu00a0weeks%20of%20weekly%20paclitaxel%20and%20bevacizumab%20therapy.%20CEC%20counts%20%28considered%20both%20as%20a%20continuous%20variable%20and%20using%20the%20previously%20described%2020%20CEC%5C%2F4%5Cu00a0ml%20cutoff%29%20were%20associated%20with%20clinical%20characteristics%20and%20progression-free%20survival%20%28PFS%29.%5CnRESULTS%3A%20CEC%20count%20was%20obtained%20in%20251%20patients%20at%20baseline%20and%20in%20207%20patients%20at%204%5Cu00a0weeks.%20Median%20baseline%20CEC%20count%20was%2022%20CEC%5C%2F4%5Cu00a0ml%20%28range%200-2231%29.%20Baseline%20CEC%20counts%20were%20associated%20with%20performance%20status%20%28p%5Cu2009%3D%5Cu20090.02%29.%20No%20statistically%20significant%20change%20in%20CEC%20counts%20was%20observed%20between%20baseline%20and%204%5Cu00a0weeks%20of%20therapy.%20High%20baseline%20CEC%20count%20was%20associated%20with%20shorter%20PFS%20in%20univariate%20and%20multivariate%20analyses%20%28continuous%3A%20p%5Cu2009%26lt%3B%5Cu20090.001%3B%20dichotomized%3A%20HR%201.52%2C%2095%25%20CI%20%5B1.15-2.02%5D%2C%20p%5Cu2009%3D%5Cu20090.004%29.%20CEC%20counts%20at%204%5Cu00a0weeks%20had%20no%20prognostic%20impact.%5CnCONCLUSION%3A%20This%20study%20confirms%20that%20CEC%20count%20may%20be%20associated%20with%20the%20outcome%20of%20mBC%20patients%20treated%20with%20chemotherapy%20and%20bevacizumab.%20However%2C%20discrepancies%20with%20previous%20reports%20in%20terms%20of%20both%20the%20timing%20of%20CEC%20count%20and%20the%20direction%20of%20the%20prognostic%20impact%20warrant%20further%20clinical%20investigation.%22%2C%22date%22%3A%22Nov%2026%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10456-019-09697-7%22%2C%22ISSN%22%3A%221573-7209%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22JEW2SA67%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Orion%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BOrion%2C%20C.%2C%20M.%20Dinulescu%2C%20S.%20Dalac-Rat%2C%20D.%20Giacchero%2C%20T.%20Jouary%2C%20C.%20Lebb%26%23xE9%3B%2C%20M.-T.%20Leccia%2C%20et%20al.%20%26%23x201C%3B%5BStage%20III%20melanoma%3A%20Sentinel%20node%20biopsy%2C%20completion%20lymph%20node%20dissection%20and%20prospects%20of%20adjuvant%20therapy.%20A%20French%20national%20survey%20on%20current%20and%20envisaged%20practices%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnales%20De%20Dermatologie%20Et%20De%20Venereologie%26lt%3B%5C%2Fi%26gt%3B%2C%20November%2021%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annder.2019.08.018%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annder.2019.08.018%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BStage%20III%20melanoma%3A%20Sentinel%20node%20biopsy%2C%20completion%20lymph%20node%20dissection%20and%20prospects%20of%20adjuvant%20therapy.%20A%20French%20national%20survey%20on%20current%20and%20envisaged%20practices%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Orion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Dinulescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Dalac-Rat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Giacchero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Jouary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lebb%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.-T.%22%2C%22lastName%22%3A%22Leccia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Maubec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mortier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dupuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Groupe%20de%20canc%5Cu00e9rologie%20cutan%5Cu00e9e%20de%20la%20Soci%5Cu00e9t%5Cu00e9%20fran%5Cu00e7aise%20de%20dermatologie%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20recent%20publication%20of%20randomized%20trials%20investigating%20the%20efficacy%20of%20adjuvant%20therapy%20and%20completion%20lymph%20node%20dissection%20at%20microscopic%20stage%20III%20melanoma%20calls%20for%20a%20reappraisal%20of%20melanoma%20management%20from%20different%20angles%3A%20indications%20for%20sentinel%20lymph%20node%20biopsy%2C%20indications%20for%20completion%20lymph%20node%20dissection%20in%20microscopic-stage%20disease%2C%20and%20adjuvant%20therapies.%20Our%20objective%20was%20to%20evaluate%20current%20practices%20and%20to%20question%20French%20onco-dermatologists%20about%20any%20changes%20they%20envisaged%20in%20their%20practices%20in%20the%20light%20of%20recent%20publications.%5CnMETHODS%3A%20We%20conducted%20a%20national%20survey%20among%20members%20of%20the%20Cutaneous%20Oncology%20Group%20of%20the%20French%20Society%20of%20Dermatology%20in%20October%202017.%5CnRESULTS%3A%20Forty%20French%20health%20centers%20were%20included%2C%20and%2053%5Cu00a0individual%20responses%20were%20collected.%20Sentinel%20lymph%20node%20biopsy%20for%20melanoma%20was%20performed%20at%2075%5Cu00a0%25%20of%20the%20centers.%20Before%20the%20summer%20of%202017%5Cu00a0and%20the%20publication%20of%20MSLT-II%20%28proving%20the%20absence%20of%20any%20therapeutic%20benefits%20for%20complete%20lymph%20node%20dissection%20in%20microscopic%20stage%20III%20melanoma%29%2C%20when%20a%20positive%20sentinel%20lymph%20node%20was%20diagnosed%2C%20immediate%20completion%20lymph%20node%20dissection%20was%20performed%20at%2090%5Cu00a0%25%20of%20the%20centers.%20After%20the%20publication%20of%20MSLT-II%2C%2045%5Cu00a0%25%20of%20the%20respondents%20considered%20stopping%20this%20practice.%20The%20risk-benefit%20ratio%20prompted%20prescription%20of%20nivolumab%20and%20of%20combined%20dabrafenib%2Btrametinib%20as%20adjuvant%20therapy%20by%20respectively%2096%5Cu00a0%25%20and%2079%5Cu00a0%25%20of%20respondents%2C%20while%20the%20corresponding%20rates%20for%20interferon%20and%20ipilimumab%20were%20only%2021%5Cu00a0%25%20and%2015%5Cu00a0%25.%5CnCONCLUSION%3A%20Early%20melanoma%20management%20stands%20on%20the%20verge%20of%20major%20changes%20thanks%20to%20the%20arrival%20of%20efficient%20adjuvant%20therapies%20and%20a%20decrease%20in%20immediate%20completion%20lymph%20node%20dissections%20for%20patients%20with%20microscopic%20stage%20III%20is%20also%20anticipated.%22%2C%22date%22%3A%22Nov%2021%2C%202019%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annder.2019.08.018%22%2C%22ISSN%22%3A%220151-9638%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22QB5X5IUL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Piau%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPiau%2C%20Antoine%2C%20Gilles%20Bourgade%2C%20Caroline%20Berbon%2C%20Fati%20Nourhashemi%2C%20Camille%20Louit%2C%20and%20Laurent%20Balardy.%20%26%23x201C%3BAccess%20to%20Individualized%20Oncology%20Care%20for%20Older%20Patients%20in%20Complex%20Healthcare%20Networks%3A%20The%20Skilled%20Nurse%20Option.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Geriatric%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2C%20November%2015%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jgo.2019.10.014%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jgo.2019.10.014%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Access%20to%20individualized%20oncology%20care%20for%20older%20patients%20in%20complex%20healthcare%20networks%3A%20The%20skilled%20nurse%20option%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Piau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Bourgade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Berbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fati%22%2C%22lastName%22%3A%22Nourhashemi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Louit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Balardy%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Nov%2015%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jgo.2019.10.014%22%2C%22ISSN%22%3A%221879-4076%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22Y97GQTVG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Balaguer%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBalaguer%2C%20Mathieu%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20Farinas%2C%20Pascale%20Fichaux-Bourin%2C%20Mich%26%23xE8%3Ble%20Puech%2C%20Julien%20Pinquier%2C%20and%20Virginie%20Woisard.%20%26%23x201C%3BValidation%20of%20the%20French%20Versions%20of%20the%20Speech%20Handicap%20Index%20and%20the%20Phonation%20Handicap%20Index%20in%20Patients%20Treated%20for%20Cancer%20of%20the%20Oral%20Cavity%20or%20Oropharynx.%26%23x201D%3B%20%26lt%3Bi%26gt%3BFolia%20Phoniatrica%20et%20Logopaedica%3A%20Official%20Organ%20of%20the%20International%20Association%20of%20Logopedics%20and%20Phoniatrics%20%28IALP%29%26lt%3B%5C%2Fi%26gt%3B%2C%20November%2015%2C%202019%2C%201%26%23x2013%3B14.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1159%5C%2F000503448%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1159%5C%2F000503448%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Validation%20of%20the%20French%20Versions%20of%20the%20Speech%20Handicap%20Index%20and%20the%20Phonation%20Handicap%20Index%20in%20Patients%20Treated%20for%20Cancer%20of%20the%20Oral%20Cavity%20or%20Oropharynx%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Balaguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Farinas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Fichaux-Bourin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mich%5Cu00e8le%22%2C%22lastName%22%3A%22Puech%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Pinquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Woisard%22%7D%5D%2C%22abstractNote%22%3A%22CONTEXT%3A%20Nowadays%2C%20clinical%20tools%20are%20available%20to%20evaluate%20the%20functional%20impact%20of%20speech%20disorders%20in%20neurological%20conditions%2C%20but%20few%20are%20validated%20in%20oncology.%20Because%20of%20their%20location%2C%20cancers%20of%20the%20upper%20aerodigestive%20tract%20directly%20impact%20patients%26%23039%3B%20communication%20skills.%20Two%20questionnaires%20exist%20in%20French%2C%20the%20Speech%20Handicap%20Index%20%28SHI%29%20and%20the%20Phonation%20Handicap%20Index%20%28PHI%29%2C%20but%20none%20are%20specifically%20validated%20for%20the%20head%20and%20neck%20cancer%20population.%20Our%20aim%20is%20to%20evaluate%20the%20validity%20of%20these%202%20questionnaires%20in%20a%20population%20of%20patients%20treated%20for%20oral%20cavity%20or%20oropharyngeal%20cancer.%5CnMATERIAL%20AND%20METHOD%3A%20Eighty-seven%20patients%20treated%20for%20cancer%20of%20the%20oral%20cavity%20or%20oropharynx%2C%20and%2021%20controls%20filled%20in%20the%20questionnaires%20during%20a%20consultation%20or%201-day%20hospitalization.%20Validation%20was%20studied%20by%20the%20analysis%20of%20convergent%20and%20discriminant%20validity%2C%20clinical%20validity%2C%20criterion%20validity%2C%20and%20internal%20consistency.%5CnRESULTS%3A%20The%202%20questionnaires%20present%20a%20coherent%20structure%20in%202%20distinct%20dimensions%20for%20the%20SHI%2C%20and%20in%203%20dimensions%20for%20the%20PHI.%20Both%20tools%20discriminate%20patients%20and%20healthy%20subjects%20%28p%20value%20%26lt%3B0.001%2C%20Mann-Whitney%20test%29.%20The%20comparison%20of%20the%20SHI%20and%20PHI%20scores%20with%20the%20%26quot%3Bsocial%20role%20functioning%26quot%3B%20dimension%20of%20the%20Medical%20Outcome%20Study%20Short%20Form%2036%20chosen%20as%20a%20reference%20shows%20similar%20performances%20for%20the%202%20questionnaires%20%28%5Cu03c1%20%26gt%3B%200.42%29.%20Lastly%2C%20the%20internal%20consistency%20is%20good%20%28Cronbach%26%23039%3Bs%20%5Cu03b1%20%26gt%3B%200.71%29.%5CnCONCLUSION%3A%20In%20patients%20treated%20for%20oral%20cavity%20or%20oropharyngeal%20cancer%2C%20the%20SHI%20and%20PHI%20are%202%20valid%20and%20reliable%20tools%20for%20the%20self-assessment%20of%20speech%20disability.%20A%20limitation%20can%20be%20found%20about%20criterion%20validity%2C%20because%20a%20true%20gold%20standard%20does%20not%20exist%20at%20the%20moment.%20However%2C%20the%20reduced%20number%20of%20questions%20of%20the%20PHI%2C%20which%20implies%20a%20shorter%20completion%2C%20leads%20to%20prefer%20this%20tool%20over%20the%20SHI.%22%2C%22date%22%3A%22Nov%2015%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1159%5C%2F000503448%22%2C%22ISSN%22%3A%221421-9972%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22N2Y6QVUW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontfort%2C%20Anne%2C%20Carine%20Dufau%2C%20C%26%23xE9%3Bline%20Colacios%2C%20Nathalie%20Andrieu-Abadie%2C%20Thierry%20Levade%2C%20Thomas%20Filleron%2C%20Jean-Pierre%20Delord%2C%20Maha%20Ayyoub%2C%20Nicolas%20Meyer%2C%20and%20Bruno%20S%26%23xE9%3Bgui.%20%26%23x201C%3BAnti-TNF%2C%20a%20Magic%20Bullet%20in%20Cancer%20Immunotherapy%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20for%20Immunotherapy%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%207%2C%20no.%201%20%28November%2014%2C%202019%29%3A%20303.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40425-019-0802-y%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40425-019-0802-y%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-TNF%2C%20a%20magic%20bullet%20in%20cancer%20immunotherapy%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22Immune%20checkpoint%20blockers%20%28ICB%29%20have%20revolutionized%20cancer%20therapy.%20However%2C%20complete%20response%20is%20observed%20in%20a%20minority%20of%20patients%20and%20most%20patients%20develop%20immune-related%20adverse%20events%20%28irAEs%29.%20These%20include%20colitis%2C%20which%20can%20be%20treated%20with%20anti-tumor%20necrosis%20factor%20%28TNF%29%20antibodies%20such%20as%20Infliximab.%20In%20a%20recent%20issue%20of%20the%20Journal%20for%20ImmunoTherapy%20of%20Cancer%2C%20Badran%20et%20al.%20reported%20that%20co-administering%20Infliximab%20together%20with%20ICB%20to%20five%20cancer%20patients%20prevents%20colitis%20recurrence%2C%20with%20four%20of%20them%20exhibiting%20overall%20disease%20stability.%20The%20basis%20for%20this%20treatment%20strategy%20stemmed%20from%20our%20pre-clinical%20demonstration%20that%20TNF%20contributes%20to%20resistance%20to%20anti-PD-1%20therapy.%20In%20agreement%20with%20this%20concept%2C%20we%20have%20shown%20that%20TNF%20blockers%20improve%20the%20anti-tumor%20therapeutic%20activity%20of%20ICB%20in%20mice%20and%20based%20on%20these%20findings%20we%20are%20currently%20evaluating%20the%20combination%20in%20melanoma%20patients%20enrolled%20in%20the%20TICIMEL%20clinical%20trial.%20Herein%2C%20%28i%29%20we%20discuss%20the%20scientific%20rationale%20for%20combining%20anti-TNF%20and%20ICB%20in%20cancer%20patients%2C%20%28ii%29%20comment%20on%20the%20paper%20published%20by%20Badran%20et%20al.%20and%20%28iii%29%20provide%20the%20TICIMEL%20clinical%20trial%20design.%22%2C%22date%22%3A%22Nov%2014%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40425-019-0802-y%22%2C%22ISSN%22%3A%222051-1426%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22NYQHHVDT%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marion%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMarion%2C%20Olivier%2C%20Sebastien%20Lhomme%2C%20Manon%20Nayrac%2C%20Martine%20Dubois%2C%20M%26%23xE9%3Blanie%20Pucelle%2C%20Mary%20Requena%2C%20Marion%20Migueres%2C%20et%20al.%20%26%23x201C%3BHepatitis%20E%20Virus%20Replication%20in%20Human%20Intestinal%20Cells.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGut%26lt%3B%5C%2Fi%26gt%3B%2C%20November%2014%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fgutjnl-2019-319004%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fgutjnl-2019-319004%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hepatitis%20E%20virus%20replication%20in%20human%20intestinal%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Marion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Lhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Nayrac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Pucelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Requena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Migueres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Abravanel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Marie%22%2C%22lastName%22%3A%22Peron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Carrere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Suc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Delobel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nassim%22%2C%22lastName%22%3A%22Kamar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Izopet%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Hepatitis%20E%20virus%20%28HEV%29%2C%20one%20of%20the%20most%20common%20agent%20of%20acute%20hepatitis%20worldwide%2C%20is%20mainly%20transmitted%20enterically%2C%20via%20contaminated%20water%20for%20HEV%20genotypes%201%20%28HEV1%29%20and%20HEV2%2C%20or%20by%20eating%20raw%20or%20undercooked%20infected%20meat%20for%20HEV%20genotype%203%20%28HEV3%29%20and%20HEV4.%20However%2C%20little%20is%20known%20about%20how%20the%20ingested%20HEV%20reaches%20the%20liver%20or%20its%20ability%20to%20replicate%20in%20intestinal%20cells.%5CnDESIGN%3A%20We%20developed%20human%20primary%20cultures%20of%20small%20intestine%20epithelial%20cells%20and%20intestinal%20explants%20obtained%20from%20small%20bowel%20resections.%20The%20epithelial%20cells%20were%20also%20polarised%20on%20transwells.%20Cells%20were%20infected%20with%20Kernow-p6%20strain%20or%20clinically%20derived%20virions.%5CnRESULTS%3A%20Primary%20intestinal%20cells%20supported%20the%20growth%20of%20Kernow-p6%20strain%20and%20HEV1%20and%20HEV3%20clinically%20derived%20virions.%20Polarised%20enterocytes%20infected%20with%20HEV1%20and%20HEV3%20strains%20released%20HEV%20particles%20vectorially%3A%20mostly%20into%20the%20apical%20compartment%20with%20a%20little%20basally.%20Iodixanol%20density%20gradient%20centrifugation%20of%20enterocyte-derived%20HEV%20virions%20gave%20bands%20at%20a%20density%20of%201.06-1.08%5Cu2009g%5C%2Fcm3%2C%20corresponding%20to%20that%20of%20quasi-enveloped%20HEV%20particles.%20Ribavirin%20therapy%20inhibited%20HEV%20excretion%20from%20the%20basal%20surface%20but%20not%20from%20the%20apical%20side%20of%20infected%20human%20enterocytes.%20HEV%20virions%20also%20infected%20intestinal%20tissue%20explants.%20Lastly%2C%20HEV%20RNA%20and%20antigen%20were%20detected%20in%20the%20intestinal%20crypts%20of%20a%20chronically%20infected%20patient.%5CnCONCLUSION%3A%20HEV%20can%20replicate%20in%20intestinal%20cells%20and%20reaches%20the%20liver%20as%20quasi-enveloped%20virions.%22%2C%22date%22%3A%22Nov%2014%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fgutjnl-2019-319004%22%2C%22ISSN%22%3A%221468-3288%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22RRH4JJT4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Attal%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAttal%2C%20Michel%2C%20Paul%20G.%20Richardson%2C%20S.%20Vincent%20Rajkumar%2C%20Jesus%20San-Miguel%2C%20Meral%20Beksac%2C%20Ivan%20Spicka%2C%20Xavier%20Leleu%2C%20et%20al.%20%26%23x201C%3BIsatuximab%20plus%20Pomalidomide%20and%20Low-Dose%20Dexamethasone%20versus%20Pomalidomide%20and%20Low-Dose%20Dexamethasone%20in%20Patients%20with%20Relapsed%20and%20Refractory%20Multiple%20Myeloma%20%28ICARIA-MM%29%3A%20A%20Randomised%2C%20Multicentre%2C%20Open-Label%2C%20Phase%203%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BLancet%20%28London%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%20November%2014%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0140-6736%2819%2932556-5%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0140-6736%2819%2932556-5%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Isatuximab%20plus%20pomalidomide%20and%20low-dose%20dexamethasone%20versus%20pomalidomide%20and%20low-dose%20dexamethasone%20in%20patients%20with%20relapsed%20and%20refractory%20multiple%20myeloma%20%28ICARIA-MM%29%3A%20a%20randomised%2C%20multicentre%2C%20open-label%2C%20phase%203%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Attal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20G.%22%2C%22lastName%22%3A%22Richardson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20Vincent%22%2C%22lastName%22%3A%22Rajkumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesus%22%2C%22lastName%22%3A%22San-Miguel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meral%22%2C%22lastName%22%3A%22Beksac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Spicka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Leleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fredrik%22%2C%22lastName%22%3A%22Schjesvold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meletios%20A.%22%2C%22lastName%22%3A%22Dimopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20Shang-Yi%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiri%22%2C%22lastName%22%3A%22Minarik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michele%22%2C%22lastName%22%3A%22Cavo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Miles%22%2C%22lastName%22%3A%22Prince%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Mac%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20P.%22%2C%22lastName%22%3A%22Corzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Campana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solenn%22%2C%22lastName%22%3A%22Le-Guennec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Dubin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20C.%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ICARIA-MM%20study%20group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Isatuximab%20is%20a%20monoclonal%20antibody%20that%20binds%20a%20specific%20epitope%20on%20the%20human%20CD38%20receptor%20and%20has%20antitumour%20activity%20via%20multiple%20mechanisms%20of%20action.%20In%20a%20previous%20phase%201b%20study%2C%20around%2065%25%20of%20patients%20with%20relapsed%20and%20refractory%20multiple%20myeloma%20achieved%20an%20overall%20response%20with%20a%20combination%20of%20isatuximab%20with%20pomalidomide%20and%20low-dose%20dexamethasone.%20The%20aim%20of%20this%20study%20was%20to%20determine%20the%20progression-free%20survival%20benefit%20of%20isatuximab%20plus%20pomalidomide%20and%20dexamethasone%20compared%20with%20pomalidomide%20and%20dexamethasone%20in%20patients%20with%20relapsed%20and%20refractory%20multiple%20myeloma.%5CnMETHODS%3A%20We%20did%20a%20randomised%2C%20multicentre%2C%20open-label%2C%20phase%203%20study%20at%20102%20hospitals%20in%2024%20countries%20in%20Europe%2C%20North%20America%2C%20and%20the%20Asia-Pacific%20regions.%20Eligible%20participants%20were%20adult%20patients%20with%20relapsed%20and%20refractory%20multiple%20myeloma%20who%20had%20received%20at%20least%20two%20previous%20lines%20of%20treatment%2C%20including%20lenalidomide%20and%20a%20proteasome%20inhibitor.%20Patients%20were%20excluded%20if%20they%20were%20refractory%20to%20previous%20treatment%20with%20an%20anti-CD38%20monoclonal%20antibody.%20We%20randomly%20assigned%20patients%20%281%3A1%29%20to%20either%20isatuximab%2010%20mg%5C%2Fkg%20plus%20pomalidomide%204%20mg%20plus%20dexamethasone%2040%20mg%20%2820%20mg%20for%20patients%20aged%20%5Cu226575%20years%29%2C%20or%20pomalidomide%204%20mg%20plus%20dexamethasone%2040%20mg.%20Randomisation%20was%20done%20using%20interactive%20response%20technology%20and%20stratified%20according%20to%20the%20number%20of%20previous%20lines%20of%20treatment%20%282-3%20vs%20%26gt%3B3%29%20and%20age%20%28%26lt%3B75%20years%20vs%20%5Cu226575%20years%29.%20Treatments%20were%20assigned%20based%20on%20a%20permuted%20blocked%20randomisation%20scheme%20with%20a%20block%20size%20of%20four.%20The%20isatuximab-pomalidomide-dexamethasone%20group%20received%20isatuximab%20intravenously%20on%20days%201%2C%208%2C%2015%2C%20and%2022%20in%20the%20first%2028-day%20cycle%2C%20then%20on%20days%201%20and%2015%20in%20subsequent%20cycles.%20Both%20groups%20received%20oral%20pomalidomide%20on%20days%201%20to%2021%20in%20each%20cycle%2C%20and%20oral%20or%20intravenous%20dexamethasone%20on%20days%201%2C%208%2C%2015%2C%20and%2022%20of%20each%20cycle.%20Treatment%20continued%20until%20disease%20progression%2C%20unacceptable%20toxicity%2C%20or%20consent%20withdrawal.%20Dose%20reductions%20for%20adverse%20reactions%20were%20permitted%20for%20pomalidomide%20and%20dexamethasone%2C%20but%20not%20for%20isatuximab.%20The%20primary%20endpoint%20was%20progression-free%20survival%2C%20determined%20by%20an%20independent%20response%20committee%20and%20assessed%20in%20the%20intention-to-treat%20population.%20Safety%20was%20assessed%20in%20all%20participants%20who%20received%20at%20least%20one%20dose%20of%20study%20drug.%20This%20study%20is%20registered%20at%20ClinicalTrials.gov%2C%20number%20NCT02990338.%5CnFINDINGS%3A%20Between%20Jan%2010%2C%202017%2C%20and%20Feb%202%2C%202018%2C%20we%20randomly%20assigned%20307%20patients%20to%20treatment%3A%20154%20to%20isatuximab-pomalidomide-dexamethasone%2C%20and%20153%20to%20pomalidomide-dexamethasone.%20At%20a%20median%20follow-up%20of%2011%5Cu00b76%20months%20%28IQR%2010%5Cu00b71-13%5Cu00b79%29%2C%20median%20progression-free%20survival%20was%2011%5Cu00b75%20months%20%2895%25%20CI%208%5Cu00b79-13%5Cu00b79%29%20in%20the%20isatuximab-pomalidomide-dexamethasone%20group%20versus%206%5Cu00b75%20months%20%284%5Cu00b75-8%5Cu00b73%29%20in%20the%20pomalidomide-dexamethasone%20group%3B%20hazard%20ratio%200%5Cu00b7596%2C%2095%25%20CI%200%5Cu00b744-0%5Cu00b781%3B%20p%3D0%5Cu00b7001%20by%20stratified%20log-rank%20test.%20The%20most%20frequent%20treatment-emergent%20adverse%20events%20%28any%20grade%3B%20isatuximab-pomalidomide-dexamethasone%20vs%20pomalidomide-dexamethasone%29%20were%20infusion%20reactions%20%2856%20%5B38%25%5D%20vs%200%29%2C%20upper%20respiratory%20tract%20infections%20%2843%20%5B28%25%5D%20vs%2026%20%5B17%25%5D%29%2C%20and%20diarrhoea%20%2839%20%5B26%25%5D%20vs%2029%20%5B20%25%5D%29.%20Adverse%20events%20with%20a%20fatal%20outcome%20were%20reported%20in%2012%20patients%20%288%25%29%20in%20the%20isatuximab-pomalidomide-dexamethasone%20group%20and%2014%20%289%25%29%20in%20the%20pomalidomide-dexamethasone%20group.%20Deaths%20due%20to%20treatment-related%20adverse%20events%20were%20reported%20for%20one%20patient%20%28%26lt%3B1%25%29%20in%20the%20isatuximab-pomalidomide-dexamethasone%20group%20%28sepsis%29%20and%20two%20%281%25%29%20in%20the%20pomalidomide-dexamethasone%20group%20%28pneumonia%20and%20urinary%20tract%20infection%29.%5CnINTERPRETATION%3A%20The%20addition%20of%20isatuximab%20to%20pomalidomide-dexamethasone%20significantly%20improves%20progression-free%20survival%20in%20patients%20with%20relapsed%20and%20refractory%20multiple%20myeloma.%20Isatuximab%20is%20an%20important%20new%20treatment%20option%20for%20the%20management%20of%20relapsed%20and%20refractory%20myeloma%2C%20particularly%20for%20patients%20who%20become%20refractory%20to%20lenalidomide%20and%20a%20proteasome%20inhibitor.%5CnFUNDING%3A%20Sanofi.%20VIDEO%20ABSTRACT.%22%2C%22date%22%3A%22Nov%2014%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS0140-6736%2819%2932556-5%22%2C%22ISSN%22%3A%221474-547X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22BT6EE22E%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLe%2C%20Dung%20T.%2C%20Tae%20Won%20Kim%2C%20Eric%20Van%20Cutsem%2C%20Ravit%20Geva%2C%20Dirk%20J%26%23xE4%3Bger%2C%20Hiroki%20Hara%2C%20Matthew%20Burge%2C%20et%20al.%20%26%23x201C%3BPhase%20II%20Open-Label%20Study%20of%20Pembrolizumab%20in%20Treatment-Refractory%2C%20Microsatellite%20Instability-High%5C%2FMismatch%20Repair-Deficient%20Metastatic%20Colorectal%20Cancer%3A%20KEYNOTE-164.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Clinical%20Oncology%3A%20Official%20Journal%20of%20the%20American%20Society%20of%20Clinical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2C%20November%2014%2C%202019%2C%20JCO1902107.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.19.02107%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.19.02107%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Phase%20II%20Open-Label%20Study%20of%20Pembrolizumab%20in%20Treatment-Refractory%2C%20Microsatellite%20Instability-High%5C%2FMismatch%20Repair-Deficient%20Metastatic%20Colorectal%20Cancer%3A%20KEYNOTE-164%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dung%20T.%22%2C%22lastName%22%3A%22Le%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tae%20Won%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Van%20Cutsem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ravit%22%2C%22lastName%22%3A%22Geva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%22%2C%22lastName%22%3A%22J%5Cu00e4ger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroki%22%2C%22lastName%22%3A%22Hara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Burge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bert%22%2C%22lastName%22%3A%22O%27Neil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petr%22%2C%22lastName%22%3A%22Kavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takayuki%22%2C%22lastName%22%3A%22Yoshino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosine%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroya%22%2C%22lastName%22%3A%22Taniguchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Elez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salah-Eddin%22%2C%22lastName%22%3A%22Al-Batran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20M.%22%2C%22lastName%22%3A%22Boland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Todd%22%2C%22lastName%22%3A%22Crocenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chloe%20E.%22%2C%22lastName%22%3A%22Atreya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%22%2C%22lastName%22%3A%22Cui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tong%22%2C%22lastName%22%3A%22Dai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Marinello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%20A.%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Andr%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20KEYNOTE-164%20%28NCT02460198%29%20evaluated%20the%20antitumor%20activity%20of%20pembrolizumab%20in%20previously%20treated%2C%20metastatic%2C%20microsatellite%20instability-high%5C%2Fmismatch%20repair-deficient%20%28MSI-H%5C%2FdMMR%29%20colorectal%20cancer%20%28CRC%29.%5CnMETHODS%3A%20This%20phase%20II%20open-label%20study%20involved%20128%20centers%20worldwide.%20Eligible%20patients%20were%20age%20%5Cu2265%2018%20years%20and%20had%20metastatic%20MSI-H%5C%2FdMMR%20CRC%20treated%20with%20%5Cu2265%202%20prior%20lines%20of%20standard%20therapy%2C%20including%20fluoropyrimidine%2C%20oxaliplatin%2C%20and%20irinotecan%20with%20or%20without%20anti-vascular%20endothelial%20growth%20factor%5C%2Fepidermal%20growth%20factor%20receptor%20monoclonal%20antibody%20%28cohort%20A%29%20or%20%5Cu2265%201%20prior%20line%20of%20therapy%20%28cohort%20B%29.%20MSI-H%5C%2FdMMR%20status%20was%20assessed%20locally.%20Patients%20received%20pembrolizumab%20200%20mg%20every%203%20weeks%20for%20up%20to%202%20years%20until%20progression%2C%20unacceptable%20toxicity%2C%20or%20withdrawal.%20The%20primary%20end%20point%20was%20objective%20response%20rate%20by%20RECIST%20version%201.1%20by%20independent%20central%20review.%20Secondary%20end%20points%20were%20duration%20of%20response%2C%20progression-free%20survival%20%28PFS%29%2C%20overall%20survival%2C%20safety%2C%20and%20tolerability.%5CnRESULTS%3A%20A%20total%20of%20124%20patients%20with%20MSI-H%5C%2FdMMR%20CRC%20%2861%20in%20cohort%20A%2C%2063%20in%20cohort%20B%29%20enrolled.%20At%20data%20cutoff%2C%20median%20follow-up%20was%2031.3%20months%20%28range%2C%200.2-35.6%20months%29%20for%20cohort%20A%20and%2024.2%20months%20%28range%2C%200.1-27.1%20months%29%20for%20cohort%20B.%20Objective%20response%20rate%20was%2033%25%20%2895%25%20CI%2C%2021%25%20to%2046%25%29%20and%2033%25%20%2895%25%20CI%2C%2022%25%20to%2046%25%29%2C%20respectively%2C%20with%20median%20duration%20of%20response%20not%20reached%20in%20either%20cohort.%20Median%20PFS%20was%202.3%20months%20%2895%25%20CI%2C%202.1%20to%208.1%20months%29%20and%204.1%20months%20%2895%25%20CI%2C%202.1%20to%2018.9%20months%29.%20Median%20overall%20survival%20was%2031.4%20months%20%2895%25%20CI%2C%2021.4%20months%20to%20not%20reached%29%20and%20not%20reached%20%2895%25%20CI%2C%2019.2%20months%20to%20not%20reached%29.%20Treatment-related%20grade%203-4%20adverse%20events%20occurred%20in%2010%20patients%20%2816%25%29%20in%20cohort%20A%20and%208%20%2813%25%29%20in%20cohort%20B%2C%20with%20the%20most%20common%20occurring%20in%20%5Cu2265%202%20patients%20being%20pancreatitis%2C%20fatigue%2C%20increased%20alanine%20aminotransferase%2C%20and%20increased%20lipase%20%282%20patients%20each%3B%203%25%29%20in%20cohort%20A.%5CnCONCLUSION%3A%20Pembrolizumab%20is%20effective%20with%20a%20manageable%20safety%20profile%20in%20patients%20with%20MSI-H%5C%2FdMMR%20CRC.%22%2C%22date%22%3A%22Nov%2014%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1200%5C%2FJCO.19.02107%22%2C%22ISSN%22%3A%221527-7755%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22ZJZR8A4N%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sarkozy%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSarkozy%2C%20Clementine%2C%20Stacy%20Hung%2C%20Katsuyoshi%20Takata%2C%20Elizabeth%20Chavez%2C%20Tomohiro%20Aoki%2C%20Gerben%20Duns%2C%20Graham%20W.%20Slack%2C%20et%20al.%20%26%23x201C%3BMutational%20Landscape%20of%20Grey%20Zone%20Lymphoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBlood%26lt%3B%5C%2Fi%26gt%3B%20134%2C%20no.%20Supplement_1%20%28November%2013%2C%202019%29%3A%2021.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2019-127375%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2019-127375%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mutational%20Landscape%20of%20Grey%20Zone%20Lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clementine%22%2C%22lastName%22%3A%22Sarkozy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stacy%22%2C%22lastName%22%3A%22Hung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katsuyoshi%22%2C%22lastName%22%3A%22Takata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Chavez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomohiro%22%2C%22lastName%22%3A%22Aoki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerben%22%2C%22lastName%22%3A%22Duns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%20W.%22%2C%22lastName%22%3A%22Slack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adele%22%2C%22lastName%22%3A%22Telenius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomoko%22%2C%22lastName%22%3A%22Miyata-Takata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Vigan%5Cu00f2%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%20Jo%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Damotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susana%22%2C%22lastName%22%3A%22Ben-Neriah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiane%22%2C%22lastName%22%3A%22Copie-Bergman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anja%22%2C%22lastName%22%3A%22Mottok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Salles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kerry%20J.%22%2C%22lastName%22%3A%22Savage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Traverse-Glehen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Steidl%22%7D%5D%2C%22abstractNote%22%3A%22DISCLOSURES%3A%20Sarkozy%3A%20Takeda%3A%20Research%20Funding.%20Salles%3AMerck%3A%20Consultancy%2C%20Honoraria%2C%20Membership%20on%20an%20entity%26%23039%3Bs%20Board%20of%20Directors%20or%20advisory%20committees%3B%20Novartis%2C%20Servier%2C%20AbbVie%2C%20Karyopharm%2C%20Kite%2C%20MorphoSys%3A%20Consultancy%2C%20Honoraria%2C%20Membership%20on%20an%20entity%26%23039%3Bs%20Board%20of%20Directors%20or%20advisory%20committees%2C%20Other%3A%20Educational%20events%3B%20Autolus%3A%20Consultancy%2C%20Membership%20on%20an%20entity%26%23039%3Bs%20Board%20of%20Directors%20or%20advisory%20committees%3B%20Takeda%3A%20Consultancy%2C%20Honoraria%2C%20Membership%20on%20an%20entity%26%23039%3Bs%20Board%20of%20Directors%20or%20advisory%20committees%2C%20Other%3A%20Educational%20events%3B%20Epizyme%3A%20Consultancy%2C%20Honoraria%3B%20BMS%3A%20Honoraria%3B%20Amgen%3A%20Honoraria%2C%20Other%3A%20Educational%20events%3B%20Roche%2C%20Janssen%2C%20Gilead%2C%20Celgene%3A%20Consultancy%2C%20Honoraria%2C%20Membership%20on%20an%20entity%26%23039%3Bs%20Board%20of%20Directors%20or%20advisory%20committees%2C%20Other%3A%20Educational%20events.%20Savage%3ABMS%2C%20Merck%2C%20Novartis%2C%20Verastem%2C%20Abbvie%2C%20Servier%2C%20and%20Seattle%20Genetics%3A%20Consultancy%2C%20Honoraria%3B%20Seattle%20Genetics%2C%20Inc.%3A%20Consultancy%2C%20Honoraria%2C%20Research%20Funding.%20Scott%3ACelgene%3A%20Consultancy%3B%20Roche%5C%2FGenentech%3A%20Research%20Funding%3B%20Janssen%3A%20Consultancy%2C%20Research%20Funding%3B%20NanoString%3A%20Patents%20%26amp%3B%20Royalties%3A%20Named%20inventor%20on%20a%20patent%20licensed%20to%20NanoSting%20%5BInstitution%5D%2C%20Research%20Funding.%20Steidl%3AJuno%20Therapeutics%3A%20Consultancy%3B%20Tioma%3A%20Research%20Funding%3B%20Roche%3A%20Consultancy%3B%20Bristol-Myers%20Squibb%3A%20Research%20Funding%3B%20Nanostring%3A%20Patents%20%26amp%3B%20Royalties%3A%20Filed%20patent%20on%20behalf%20of%20BC%20Cancer%3B%20Seattle%20Genetics%3A%20Consultancy%3B%20Bayer%3A%20Consultancy.%22%2C%22date%22%3A%22Nov%2013%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood-2019-127375%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22TTEL6LTR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Legros%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLegros%2C%20Laurence%2C%20Franck%20E.%20Nicolini%2C%20Gabriel%20Etienne%2C%20Philippe%20Rousselot%2C%20Delphine%20Rea%2C%20Stephane%20Giraudier%2C%20Agn%26%23xE8%3Bs%20Guerci%2C%20et%20al.%20%26%23x201C%3BThe%20TKI-Free%20Duration%20after%20a%20First%20Discontinuation%20Attempt%20That%20Failed%20in%20CP%20CML%20Patients%20Is%20a%20Predictive%20Factor%20of%20TKI-Free%20Remission%20after%20a%20Second%20Attempt.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBlood%26lt%3B%5C%2Fi%26gt%3B%20134%2C%20no.%20Supplement_1%20%28November%2013%2C%202019%29%3A%2028.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2019-123719%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2019-123719%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20TKI-Free%20Duration%20after%20a%20First%20Discontinuation%20Attempt%20That%20Failed%20in%20CP%20CML%20Patients%20Is%20a%20Predictive%20Factor%20of%20TKI-Free%20Remission%20after%20a%20Second%20Attempt%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Legros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%20E.%22%2C%22lastName%22%3A%22Nicolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Etienne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rousselot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Rea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephane%22%2C%22lastName%22%3A%22Giraudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Guerci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francoise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Gardembas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Ianotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Escoffre-Barbe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerie%22%2C%22lastName%22%3A%22Coiteux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Varet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephane%22%2C%22lastName%22%3A%22Morisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois-Xavier%22%2C%22lastName%22%3A%22Mahon%22%7D%5D%2C%22abstractNote%22%3A%22DISCLOSURES%3A%20Legros%3A%20Incyte%20Biosciences%3A%20Honoraria%2C%20Research%20Funding%3B%20BMS%3A%20Honoraria%3B%20Pfizer%3A%20Honoraria%2C%20Research%20Funding%3B%20Novartis%3A%20Honoraria.%20Nicolini%3ASun%20Pharma%20Ltd%3A%20Consultancy%3B%20Incyte%20Biosciences%3A%20Honoraria%2C%20Research%20Funding%2C%20Speakers%20Bureau%3B%20Novartis%3A%20Research%20Funding%2C%20Speakers%20Bureau.%20Etienne%3ABMS%3A%20Honoraria%2C%20Speakers%20Bureau%3B%20Incyte%20Biosciences%3A%20Honoraria%2C%20Speakers%20Bureau%3B%20Pfizer%3A%20Honoraria%2C%20Speakers%20Bureau%3B%20Novartis%3A%20Consultancy%2C%20Honoraria%2C%20Speakers%20Bureau.%20Rousselot%3APfizer%3A%20Research%20Funding%3B%20Incyte%3A%20Research%20Funding.%20Rea%3ANovartis%3A%20Honoraria%2C%20Membership%20on%20an%20entity%26%23039%3Bs%20Board%20of%20Directors%20or%20advisory%20committees%3B%20Pfizer%3A%20Honoraria%2C%20Membership%20on%20an%20entity%26%23039%3Bs%20Board%20of%20Directors%20or%20advisory%20committees%3B%20BMS%3A%20Honoraria%3B%20Incyte%20Biosciences%3A%20Honoraria.%20Guerci%3AINCYTE%3A%20Consultancy%2C%20Honoraria.%20Huguet%3AIncyte%20Biosciences%3A%20Honoraria%3B%20Novartis%3A%20Honoraria%3B%20Servier%3A%20Honoraria%3B%20Jazz%20Pharmaceuticals%3A%20Honoraria%3B%20Amgen%3A%20Honoraria%3B%20BMS%3A%20Honoraria%3B%20Pfizer%3A%20Honoraria.%20Coiteux%3ANovartis%3A%20Honoraria%2C%20Speakers%20Bureau%3B%20BMS%3A%20Honoraria%2C%20Speakers%20Bureau%3B%20Incyte%20Biosciences%3A%20Honoraria%2C%20Speakers%20Bureau%3B%20Pfizer%3A%20Honoraria%2C%20Speakers%20Bureau.%20Mahon%3ANovartis%3A%20Consultancy%2C%20Honoraria%2C%20Speakers%20Bureau%3B%20BMS%3A%20Honoraria%2C%20Speakers%20Bureau%3B%20Pfizer%3A%20Honoraria%2C%20Speakers%20Bureau%3B%20Incyte%20Biosciences%3A%20Honoraria%2C%20Speakers%20Bureau.%22%2C%22date%22%3A%22Nov%2013%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood-2019-123719%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A45Z%22%7D%7D%5D%7D

Delaunay, Myriam, Grégoire Prévot, Samia Collot, Laurent Guilleminault, Alain Didier, and Julien Mazières. “Management of Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors.” European Respiratory Review: An Official Journal of the European Respiratory Society 28, no. 154 (December 31, 2019). https://doi.org/10.1183/16000617.0012-2019.

Ploussard, Guillaume, Jean-Baptiste Beauval, Marine Lesourd, Christophe Almeras, Jacques Assoun, Richard Aziza, Jean-Romain Gautier, et al. “Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-Positive Candidates for Active Surveillance on Systematic Biopsies.” Urology, December 30, 2019. https://doi.org/10.1016/j.urology.2019.10.039.

Grondin, Anthony, Eloïse Baudou, Marlène Pasquet, Sonia Pelluau, Karim Jamal-Bey, Cécile Bermot, Frederic Villega, and Emmanuel Cheuret. “Neonatal Herpes Simplex Virus-1 Recurrence with Central Nervous System Disease in Twins after Completion of a Six-Month Course of Suppressive Therapy: Case Report.” Neuropediatrics, December 30, 2019. https://doi.org/10.1055/s-0039-3402011.

Siegfried, Aurore, Julien Masliah-Planchon, Franck-Emmanuel Roux, Delphine Larrieu-Ciron, Gaelle Pierron, Yvan Nicaise, Marion Gambart, et al. “Brain Tumor with an ATXN1-NUTM1 Fusion Gene Expands the Histologic Spectrum of NUTM1-Rearranged Neoplasia.” Acta Neuropathologica Communications 7, no. 1 (December 30, 2019): 220. https://doi.org/10.1186/s40478-019-0870-8.

Manrique, Alain, David Dudoignon, Stéphanie Brun, Catherine N’Ganoa, Emmanuelle Cassol, Damien Legallois, Yoan Lavie-Badie, Denis Agostini, and Olivier Lairez. “Quantification of Myocardial 99mTc-Labeled Bisphosphonate Uptake with Cadmium Zinc Telluride Camera in Patients with Transthyretin-Related Cardiac Amyloidosis.” EJNMMI Research 9, no. 1 (December 23, 2019): 117. https://doi.org/10.1186/s13550-019-0584-8.

Koffi, K. G., D. A. Silué, C. Laurent, K. Boidy, S. Koui, G. Compaci, Z. H. Adeba, et al. “AMAFRICA, a Patient-Navigator Program for Accompanying Lymphoma Patients during Chemotherapy in Ivory Coast: A Prospective Randomized Study.” BMC Cancer 19, no. 1 (December 23, 2019): 1247. https://doi.org/10.1186/s12885-019-6478-3.

Garnache-Ottou, Francine, Chrystelle Vidal, Sabeha Biichlé, Florian Renosi, Eve Poret, Maïder Pagadoy, Maxime Desmarets, et al. “How Should We Diagnose and Treat Blastic Plasmacytoid Dendritic Cell Neoplasm Patients?” Blood Advances 3, no. 24 (December 23, 2019): 4238–51. https://doi.org/10.1182/bloodadvances.2019000647.

Hofmann, Werner, Wei Bo Li, Werner Friedland, Brian W. Miller, Balázs Madas, Manuel Bardiès, and Imre Balásházy. “Internal Microdosimetry of Alpha-Emitting Radionuclides.” Radiation and Environmental Biophysics, December 21, 2019. https://doi.org/10.1007/s00411-019-00826-w.

Zamora, Audrey, Melinda Alves, Charlotte Chollet, Nicole Therville, Tiffany Fougeray, Florence Tatin, Camille Franchet, et al. “Paclitaxel Induces Lymphatic Endothelial Cells Autophagy to Promote Metastasis.” Cell Death & Disease 10, no. 12 (December 20, 2019): 956. https://doi.org/10.1038/s41419-019-2181-1.

Massé, Julie, Caroline Truntzer, Romain Boidot, Emmanuel Khalifa, Gaëlle Pérot, Valérie Velasco, Laétitia Mayeur, et al. “Solid-Type Adenoid Cystic Carcinoma of the Breast, a Distinct Molecular Entity Enriched in NOTCH and CREBBP Mutations.” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, December 19, 2019. https://doi.org/10.1038/s41379-019-0425-3.

Franchet, Camille, and Jean-Sébastien Hoffmann. “When RAD52 Allows Mitosis to Accept Unscheduled DNA Synthesis.” Cancers 12, no. 1 (December 19, 2019). https://doi.org/10.3390/cancers12010026.

Meyrignac, Olivier, Élise Arcis, Marie-Charlotte Delchier, Fatima-Zohra Mokrane, Jean Darcourt, Hervé Rousseau, and Béatrice Bouhanick. “Impact of Cone Beam - CT on Adrenal Vein Sampling in Primary Aldosteronism.” European Journal of Radiology 124 (December 18, 2019): 108792. https://doi.org/10.1016/j.ejrad.2019.108792.

Appay, Romain, Caroline Dehais, Claude-Alain Maurage, Agusti Alentorn, Catherine Carpentier, Carole Colin, François Ducray, et al. “CDKN2A Homozygous Deletion Is a Strong Adverse Prognosis Factor in Diffuse Malignant IDH-Mutant Gliomas.” Neuro-Oncology 21, no. 12 (December 17, 2019): 1519–28. https://doi.org/10.1093/neuonc/noz124.

Mazerolle, P., T. Meresse, D. Gangloff, K. Kolsi, and A. Dupret-Bories. “Vascularized Lymph Node Transfer with Submental Free Flap.” European Annals of Otorhinolaryngology, Head and Neck Diseases, December 16, 2019. https://doi.org/10.1016/j.anorl.2019.11.004.

Ploussard, Guillaume, Cécile Manceau, Jean-Baptiste Beauval, Marine Lesourd, Christophe Almeras, Jean-Romain Gautier, Guillaume Loison, et al. “Decreased Accuracy of the Prostate Cancer EAU Risk Group Classification in the Era of Imaging-Guided Diagnostic Pathway: Proposal for a New Classification Based on MRI-Targeted Biopsies and Early Oncologic Outcomes after Surgery.” World Journal of Urology, December 14, 2019. https://doi.org/10.1007/s00345-019-03053-6.

Frigeni, Marco, Caroline Besson, Carlo Visco, Helene Fontaine, Maria Goldaniga, Marcella Visentini, Alessandro Pulsoni, et al. “Interferon-Free Compared to Interferon-Based Antiviral Regimens as First-Line Therapy for B-Cell Lymphoproliferative Disorders Associated with Hepatitis C Virus Infection.” Leukemia, December 13, 2019. https://doi.org/10.1038/s41375-019-0687-2.

Hantelys, Fransky, Anne-Claire Godet, Florian David, Florence Tatin, Edith Renaud-Gabardos, Françoise Pujol, Leila H. Diallo, et al. “Vasohibin1, a New Mouse Cardiomyocyte IRES Trans-Acting Factor That Regulates Translation during Early Hypoxia.” eLife 8 (December 9, 2019). https://doi.org/10.7554/eLife.50094.

Tang, Nicolas, Marta Bueno, Sylvain Meylan, Yann Perrot, Hoang N. Tran, Amélie Freneau, Morgane Dos Santos, et al. “Assessment of Radio-Induced Damage in Endothelial Cells Irradiated with 40 kVp, 220 kVp, and 4 MV X-Rays by Means of Micro and Nanodosimetric Calculations.” International Journal of Molecular Sciences 20, no. 24 (December 9, 2019). https://doi.org/10.3390/ijms20246204.

Péricart, Sarah, Charlotte Waysse, Aurore Siegfried, Stephanie Struski, Eric Delabesse, Camille Laurent, and Solène Evrard. “Subsequent Development of Histiocytic Sarcoma and Follicular Lymphoma: Cytogenetics and next-Generation Sequencing Analyses Provide Evidence for Transdifferentiation of Early Common Lymphoid Precursor-a Case Report and Review of Literature.” Virchows Archiv: An International Journal of Pathology, December 5, 2019. https://doi.org/10.1007/s00428-019-02691-w.

Sroussi, Marine, Reza Elaidi, Aude Fléchon, Marianne Lorcet, Delphine Borchiellini, Magalie P. Tardy, Gwenaelle Gravis, et al. “Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.” Clinical Genitourinary Cancer, December 5, 2019. https://doi.org/10.1016/j.clgc.2019.11.014.

Lambo, Sander, Susanne N. Gröbner, Tobias Rausch, Sebastian M. Waszak, Christin Schmidt, Aparna Gorthi, July Carolina Romero, et al. “The Molecular Landscape of ETMR at Diagnosis and Relapse.” Nature, December 4, 2019. https://doi.org/10.1038/s41586-019-1815-x.

Compaci, Gisèle, Cécile Conte, Lucie Oberic, Loïc Ysebaert, Guy Laurent, and Fabien Despas. “Sustained Degradation of Quality of Life in a Subgroup of Lymphoma Survivors: A Two-Year Prospective Survey.” BMC Cancer 19, no. 1 (December 3, 2019): 1178. https://doi.org/10.1186/s12885-019-6337-2.

Dubucs, Charlotte, Céline Basset, Dominique D’Aure, Monique Courtade-Saïdi, and Solène M. Evrard. “A 4-Year Retrospective Analysis of Salivary Gland Cytopathology Using the Milan System for Reporting Salivary Gland Cytology and Ancillary Studies.” Cancers 11, no. 12 (December 1, 2019). https://doi.org/10.3390/cancers11121912.

Voron, Thibault, Caroline Gronnier, Arnaud Pasquer, Jeremie Thereaux, Johan Gagniere, Gil Lebreton, Bernard Meunier, et al. “Adenocarcinoma of the Oesophagogastric Junction Siewert II: An Oesophageal Cancer Better Cured with Total Gastrectomy.” European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 45, no. 12 (December 2019): 2473–81. https://doi.org/10.1016/j.ejso.2019.07.022.

Lesur, Anne, Florence Dalenc, and Marie Beguignot. “[Adjuvant endocrine therapy in premenopausal breast cancer: a initial dedicated counseling: can it be useful for better adherence?].” Bulletin Du Cancer 106, no. 12S1 (December 2019): S28–36. https://doi.org/10.1016/S0007-4551(20)30045-X.

Vergez, François, Laetitia Largeaud, Lucie Oberic, and Jean-Baptiste Rieu. “Do Not Jump to Hasty Conclusions: All Gamma Delta T-Cells Neoplasms Are Not Aggressive!” Blood Research 54, no. 4 (December 2019): 243. https://doi.org/10.5045/br.2019.54.4.243.

Guillaume, Maeva, Valerie Moal, Cyrielle Delabaudiere, Floraine Zuberbuhler, Marie-Angèle Robic, Adrien Lannes, Sophie Metivier, et al. “Direct Comparison of the Specialised Blood Fibrosis Tests FibroMeterV2G and Enhanced Liver Fibrosis Score in Patients with Non-Alcoholic Fatty Liver Disease from Tertiary Care Centres.” Alimentary Pharmacology & Therapeutics 50, no. 11–12 (December 2019): 1214–22. https://doi.org/10.1111/apt.15529.

Kaboré, Elisé G., Charles Guenancia, Ines Vaz-Luis, Antonio Di Meglio, Barbara Pistilli, Charles Coutant, Paul Cottu, et al. “Association of Body Mass Index and Cardiotoxicity Related to Anthracyclines and Trastuzumab in Early Breast Cancer: French CANTO Cohort Study.” PLoS Medicine 16, no. 12 (December 2019): e1002989. https://doi.org/10.1371/journal.pmed.1002989.

Heidegger, Isabel, Igor Tsaur, Hendrik Borgmann, Christian Surcel, Alexander Kretschmer, Romain Mathieu, Pieter De Visschere, et al. “Hereditary Prostate Cancer - Primetime for Genetic Testing?” Cancer Treatment Reviews 81 (December 2019): 101927. https://doi.org/10.1016/j.ctrv.2019.101927.

Steinmeyer, Zara, Stéphane Gérard, Thomas Filleron, Stéphanie Lozano, Delphine Brechemier, Gabor Abellan Van Kan, Loic Mourey, et al. “Low Lean Mass and Chemotherapy Toxicity Risk in the Elderly: The Fraction Study Protocol.” BMC Cancer 19, no. 1 (November 27, 2019): 1153. https://doi.org/10.1186/s12885-019-6377-7.

Flot, Claire, Isabelle Oliver, Philippe Caron, Frédérique Savagner, Maithé Tauber, Ségolène Claeyssens, and Thomas Edouard. “Acquired von Willebrand’s Syndrome Caused by Primary Hypothyroidism in a 5-Year-Old Girl.” Journal of Pediatric Endocrinology & Metabolism: JPEM 32, no. 11 (November 26, 2019): 1295–98. https://doi.org/10.1515/jpem-2019-0082.

Vasseur, Antoine, Luc Cabel, Olivier Tredan, Marion Chevrier, Coraline Dubot, Véronique Lorgis, William Jacot, et al. “Prognostic Value of CEC Count in HER2-Negative Metastatic Breast Cancer Patients Treated with Bevacizumab and Chemotherapy: A Prospective Validation Study (UCBG COMET).” Angiogenesis, November 26, 2019. https://doi.org/10.1007/s10456-019-09697-7.

Orion, C., M. Dinulescu, S. Dalac-Rat, D. Giacchero, T. Jouary, C. Lebbé, M.-T. Leccia, et al. “[Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices].” Annales De Dermatologie Et De Venereologie, November 21, 2019. https://doi.org/10.1016/j.annder.2019.08.018.

Piau, Antoine, Gilles Bourgade, Caroline Berbon, Fati Nourhashemi, Camille Louit, and Laurent Balardy. “Access to Individualized Oncology Care for Older Patients in Complex Healthcare Networks: The Skilled Nurse Option.” Journal of Geriatric Oncology, November 15, 2019. https://doi.org/10.1016/j.jgo.2019.10.014.

Balaguer, Mathieu, Jérôme Farinas, Pascale Fichaux-Bourin, Michèle Puech, Julien Pinquier, and Virginie Woisard. “Validation of the French Versions of the Speech Handicap Index and the Phonation Handicap Index in Patients Treated for Cancer of the Oral Cavity or Oropharynx.” Folia Phoniatrica et Logopaedica: Official Organ of the International Association of Logopedics and Phoniatrics (IALP), November 15, 2019, 1–14. https://doi.org/10.1159/000503448.

Montfort, Anne, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer, and Bruno Ségui. “Anti-TNF, a Magic Bullet in Cancer Immunotherapy?” Journal for Immunotherapy of Cancer 7, no. 1 (November 14, 2019): 303. https://doi.org/10.1186/s40425-019-0802-y.

Marion, Olivier, Sebastien Lhomme, Manon Nayrac, Martine Dubois, Mélanie Pucelle, Mary Requena, Marion Migueres, et al. “Hepatitis E Virus Replication in Human Intestinal Cells.” Gut, November 14, 2019. https://doi.org/10.1136/gutjnl-2019-319004.

Attal, Michel, Paul G. Richardson, S. Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, et al. “Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study.” Lancet (London, England), November 14, 2019. https://doi.org/10.1016/S0140-6736(19)32556-5.

Le, Dung T., Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, et al. “Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, November 14, 2019, JCO1902107. https://doi.org/10.1200/JCO.19.02107.

Sarkozy, Clementine, Stacy Hung, Katsuyoshi Takata, Elizabeth Chavez, Tomohiro Aoki, Gerben Duns, Graham W. Slack, et al. “Mutational Landscape of Grey Zone Lymphoma.” Blood 134, no. Supplement_1 (November 13, 2019): 21. https://doi.org/10.1182/blood-2019-127375.

Legros, Laurence, Franck E. Nicolini, Gabriel Etienne, Philippe Rousselot, Delphine Rea, Stephane Giraudier, Agnès Guerci, et al. “The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt.” Blood 134, no. Supplement_1 (November 13, 2019): 28. https://doi.org/10.1182/blood-2019-123719.

LES MEMBRES DE L’ÉQUIPE


    



    
    
        
            

Jean-Marc Alliot
Chercheur invité / visiting researcher

LES PARTENAIRES & FINANCIERS

Centre de Recherches contre le Cancer de Toulouse (Oncopole)

Toulouse - FR

Suivez nous sur les réseaux sociaux

Suivre

Suivre

Nous contacter

+33 5 82 74 15 75

Nous rejoindre ?

Join-us

IRIT@CRCTEquipe « MICHEL LAUDET »

IRIT@CRCT :

laboratoire de cancérologie numérique « Michel Laudet »

NOS PROJETSDE RECHERCHE

Observance

Titre en cours

Titre en cours

LAM

Modélisation des cartes d’interaction moléculaire

PRODUCTIONS SCIENTIFIQUES

PUBLICATIONS 2022

PUBLICATIONS 2021

PUBLICATIONS 2020

PUBLICATIONS 2019

LES MEMBRES DE L’ÉQUIPE

LES PARTENAIRES & FINANCIERS

Pin It on Pinterest

IRIT@CRCT
Equipe « MICHEL LAUDET »

NOS PROJETS
DE RECHERCHE